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 Introduction 
Biopharmaceutical drugs have gained more and more importance in the field of pharmaceutical 
research [1] [2]. Being able to cure severe and rare diseases, the development of pharmaceutical 
products for the delivery of peptides and proteins became an important task in recent years [3] 
[4]. Challenges within the development, manufacturing, production and storage of these 
products are, that especially proteins are sensitive to a variety of external factors, like shear 
stress, temperature and pH [5] [6]. Due to poor oral absorption, peptide and protein drugs are 
typically administered parenterally. Furthermore a short half-life in the body causes a high 
frequency of administration via the parenteral route, which negatively impacts the patient 
compliance [2]. For this reason, the development of sustained release delivery systems is of 
high importance to achieve sustained blood levels with reduced side effects and improved 
patient acceptance [7].  
In the field of veterinary medicine, the focus is set on facilitating therapy for owners and 
veterinarians and to reduce distress and potential side effects for the treated animal [8]. For 
livestock breeding, the application of biopharmaceutical drugs opens new doors with respect to 
wait-times and residuals in animal products. With the application of biopharmaceutical drugs 
in a sustained release delivery system, their main drawback, the short half-life can be overcome 
[9]. As strict rules for wait times concerning milk and meat exist for small molecules due to 
accumulation, this problem is not given for peptides, e.g. G [6-D-Phe] in Gonvet®Veyx (Veyx 
Pharma GmbH) [10]. Consequently, sustained release formulations entered the marketplace in 
veterinary medicine. ProHeart® 6 by Zoetis, an injectable sustained delivery system for 
protection against the canine heartworm disease, based on lipid microparticles is FDA approved 
[11]–[13]. Another example is the application of the GnRH-agonist deslorelin via the 
subcutaneously injected lipid implant Suprelorin® by Virbac for the chemical castration in male, 
mature dogs [14] [15]. Suprelorin® was recently also investigated for taint removal of boars and 
for suppression of sexual function in male cats [16] [17]. Bovine somatotropin (recombinant 
bovine growth hormone, BST, rBGH) is the active ingredient formulated in an oily zinc 
suspension in Posilac® (Elanco Animal Health). The controlled release induces an improved 
lactation in dairy cows [8] [18] [19]. For livestock animals, the requirements are to provide an 
acceptable and effective therapy with low costs, facilitating the already existing treatment. 
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 Drug Delivery Systems for the Sustained Release of Peptides and 
Proteins 
A variety of drug delivery systems can be utilized to sustain the release of peptides and proteins. 
 Implants 
Implants usually have a cylindrical shape and can be manufactured by compression, molding 
or extrusion [20]–[22]. A distinction between biodegradable and non-biodegradable implants 
is commonly made in literature. Advantages of biodegradable implants are the lack of surgical 
removal and the high biocompatibility [2] [23] [24]. Release is mainly controlled by diffusion, 
which takes place in both degradable and non-degradable implants. Furthermore, for 
biodegradable implants also matrix erosion, swelling and osmotic effects need to be taken into 
consideration [25] [26].  
Poly (lactide-co-glycolide) (PLGA) derived implants 
The delivery of proteins via PLGA-based implants was extensively studied, revealing 
outstanding biocompatibility and degradation properties [27]–[29]. A disadvantage concerning 
implants based on PLGA is the formation of an acidic microenvironment within the implant, 
leading to an enhanced degradation of the protein and potentially covalently modified peptide 
and protein [27] [30] [31]. Nevertheless, PLGA-based implants delivering the peptide drugs 
goserelin (Zoladex®, Astra Zeneca) [32] and buserelin (Profact® Depot, Sanofi Aventis 
Deutschland GmbH) [33], as well as an in-situ forming implant containing leuprolide (Eligard®, 
Astellas) [34] are approved for breast and prostate cancer treatment, whereas Zoladex® is 
further approved for the treatment of severe endometriosis [32] [35].  
Solid lipid implants  
The manufacturing of biodegradable implants made from solid lipids, like triglycerides, also in 
combination with monoglycerides and cholesterol for the delivery of therapeutic proteins is of 
high interest in the field of controlled delivery [22] [26] [36] [37]. An advantageous production 
system is the twin-screw extrusion process, allowing to treat the lipid excipient slightly below 
the melting point which helps to avoid polymorphic changes [22] [37] [38]. Drug release can 
be managed in time frames from weeks to months [39] [40]. The addition of additives like 
polyethylene glycol (PEG) can enhance and complete the release, due to the formation of an 
interconnected pore network [26] [40] [41]. 
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 Suspensions  
Oily suspensions are suitable delivery systems for peptides and proteins intended for controlled 
release [2]. The sustained delivery is due to the formation of a depot after injection in the tissue, 
which slowly releases the drug [8]. In human as well as veterinary medicine oily suspensions 
are of high interest. In veterinary medicine, e.g. the products Excede® and Excenel® RTU by 
Zoetis containing ceftiofur and its hydrochloride, a cephalosporin against infectious diseases in 
cattle, is applied via an oily suspension [8] [42] [43] . 
 Nanoparticles 
Nanoparticles ranging from 10 to 1000 nm can e.g. be produced by spray drying  and emulsion-
based preparation methods, like hot or cold homogenization techniques [44]–[47]. Natural or 
synthetic polymers, like gelatin, PLGA, or triglycerides can be used for their preparation [46] 
[48]–[51]. Triglycerides, like tristearin, trimyristin or composed lipids like Compritol® 888 
ATO are commonly used as lipid bases upon manufacturing [52]–[54]. Regarding 
biopharmaceutical drugs, proteins like BSA and peptides like calcitonin and gonadorelin have 
been entrapped successfully into nanoparticles [55]–[58].  
 Microparticles 
Microparticles from natural and synthetic polymers, for example solid lipids [1] [59] [60], 
PLGA [61]–[63] and poly lactic acid (PLA) [64], are suitable for parenteral drug delivery. 
Various microparticulate sustained release systems are described for biopharmaceuticals [1] 
[65]–[68].  
Poly lactic acid (PLA) and Poly lactic co-glycolic acid (PLGA) microparticles 
PLGA is described as suitable polymer for the preparation of microparticles, also for protein 
and peptide delivery [24]. Recombinant human erythropoietin (rhEPO), vascular endothelial 
growth factor (VEGF) and the peptide somatostatin could be successfully entrapped into PLA 
and PLGA-based particles [3] [69] [70]. Problems arising from PLGA are changes in the 
microclimate which afford a special stabilization of the encapsulated proteins [24] [71] and the 
high costs which explain the only few available veterinary products. The drug delivery system 
SMARTshot® B12
 Prime Lamb by Virbac delivers vitamin B12 in a PLGA suspension in an oily 
vehicle for suckling lambs [8] [72]. For diabetes treatment, the PLGA-based microparticle 
system Bydureon® by AstraZeneca is approved delivering exenatide [73]. 
  
                                                                      CHAPTER ONE 
 
5 
 
Solid lipid microparticles  
Solid lipid microparticles are of particular interest for the delivery of biopharmaceuticals due 
to several advantages compared to other polymers like PLGA [1] [67] [74]–[76].The solid lipids 
are highly biocompatible and degraded by endogenous lipases [5] [23] [77]. A pH shift, which 
may destabilize peptides and proteins, cannot be observed [78]. The peptides somatostatin, 
insulin, thymocartin, desmopressin and the GnRH antagonist antide have been loaded into solid 
lipid microparticles [1] [68] [74]–[76]. The sustained delivery of proteins like BSA has also 
been realized with incorporation into lipid microparticles [79] [80]. 
 Preparation Techniques for Lipid-Based Microparticles 
Lipid-based microparticles are often produced by emulsion-based methods [81]–[83]. 
Furthermore, preparation techniques with presence of organic solvents are common [75] [76]. 
Ideally, the manufacturing technique works without an additional water phase, which may 
induce degradation or aggregation processes at the interface, and without organic solvents to 
avoid the problem of solvent residuals in lipid microparticles. 
 Hot emulsion 
This method is preferably applied for preparation of small molecule-loaded lipid microparticles. 
Lipid excipients are melted together and mixed with a hot aqueous phase containing emulsifier 
to obtain a O/W emulsion, potentially via phase inversion. Upon cooling, the lipid droplets 
solidify which leads to the formation of microparticles [84] [85]. 
 Double emulsion  
In the double emulsion method, the drug is dissolved in an aqueous phase, which is afterwards 
emulsified into a lipid melt. Often stabilizers such as gelatin or poloxamers are used. 
Subsequently, this primary emulsion is transferred into a second aqueous phase. Upon stirring 
and cooling, the microparticles solidify and can be removed by filtration [81] [86]. 
 Solvent evaporation  
The solvent evaporation method was also reported as suitable for the encapsulation of peptides 
into microparticles [68] [74]. The underlying principle is, that the solid triglyceride is dissolved 
in methylene chloride or another organic solvent and the grinded peptide afterwards added. The 
suspension is subsequently added to an aqueous solution, which might be cooled, and stirred to 
allow the evaporation of the organic solvent leading to the formation of the microparticles [74]. 
Another technique deriving from this process is the so called solvent stripping method used for 
the entrapment of the GnRH antagonist antide [76]. Other researchers also successfully 
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incorporated hepatitis B surface antigen (HbsAg) and somatostatin via a modified emulsion-
solvent evaporation method into lipid microparticles [67] [75]. 
 Spray drying 
Spray drying is an efficient drying process in a preheated airstream. Although the contact of the 
liquid phase with the hot air is quite short, this drying technique leads to a considerably higher 
thermal stress than freeze-drying [87]–[89]. For this reason, the co-current preparation method 
should be favored compared to the counter current method, as the air of the lowest temperature 
is getting in contact with the drug solution, e.g. as described for recombinant methionyl human 
growth hormone (hGH) and tissue-type plasminogen activator (t-PA) [87] [88]. To achieve a 
sustained release, atomization can either occur out of an organic solution, an emulsion or a 
suspension, whereas the removal of one phase commonly leads to the formation of 
microparticles [3] [90]–[92]. Used lipids for the spray drying process are usually triglycerides 
also in combination with emulsifiers like lecithin [91]. But also the use of other polymers like 
PLGA [90] [61], PLA [64], cellulose derivatives [93] or chitosan [94] is described in literature. 
Thus, this preparation method is used for the preparation of microparticles loaded with 
biopharmaceutical drugs, like erythropoietin and insulin [3] [95].  
 Spray congealing 
Spray congealing is related from spray drying using a similar apparatus setup with installation 
of additional parts (Figure 1-1) [1]. The lipid melt with suspended peptide or protein particles, 
is sprayed into an air stream, which is either kept at room temperature or cooled down [1] [96]–
[99]. Atomization typically occurs with the use of a two-fluid nozzle whereas compressed air 
is commonly used to disperse the melt [100] [101]. Furthermore, the use of atomization via 
ultrasound [102]–[105] and rotating discs or wheels [96] [106] [107] is described. The contact 
with the air of lower temperature leads to solidification of the produced droplets. The separation 
in different size fractions occurs in analogy to the spray drying process [108]. 
                                                                      CHAPTER ONE 
 
7 
 
 
Figure 1-1: Schematic image of the spray congealing equipment based on the Büchi B-290 Mini spray 
dryer [1] 
In literature, the successful incorporation of a variety of small molecule drugs, like 
indomethacin [102], verapamil HCl [97] and aminolevulinic acid [101] is described. The 
encapsulation of proteins via spray congealing may be critical due to thermal stress affecting 
the ternary and quaternary structure. Nevertheless the peptides insulin [1], somatostatin [75] 
and thymocartin [74] as well as proteins like BSA were successfully incorporated into spray 
congealed lipid microparticles [79] [109]. Major benefits of the spray congealing process are, 
that no further aqueous phase is needed which helps to avoid peptide or protein aggregation [5] 
[110]. 
 Estrus Synchronization 
The term estrus synchronization describes the simultaneous achievement of the fertile state in 
female animals by the help of pharmaceuticals [111]–[113]. It is a suitable tool to reduce costs 
and efforts for veterinarians and farmers, due to termination of separation of the female animals, 
as well as littering and weaning [114] [115]. Species treated to achieve estrus synchronization 
are mainly swine, but protocols do also exist for cattle, sheep, goats and mares [115]–[123]. 
Over decades, the application of synthetic gestagens turned out to be highly efficient in 
synchronizing the estrus in swine, whereas the treatment is successful for both gilts and sows 
[111] [113] [117]. Moreover, gestagen treatment leads to absence of non-responders and no 
severe side effects [113]. These advantages made this therapy to the gold-standard in estrus 
synchronization in recent years. Drawbacks of this therapy arise from the environmental entry 
of the gestagens by the produced manure [124] [125]. Analysis of the surrounding runoff to 
large agricultural holdings evidenced the presence of gestagens in levels above non-harmful 
concentrations [126] [127]. Gestagens exhibit toxicity for water organisms by leading to 
reproductive disorders or even infertility, further discussed in 1.5 [128] [129].  
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 Hormonal regulation mechanisms 
To understand the mode of action underlying estrus synchronization, the hormonal regulation 
of sex hormones in female mammalians is briefly discussed. Under control of luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) progesterone and estrogen are released. 
LH and FSH release again is controlled by the decapeptide gonadotropin-releasing hormone 
(GnRH), also referred to as luteinizing hormone-releasing hormone (LHRH), with the sequence 
p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 [130]–[133]. A single or pulsatile 
application of GnRH or its analogues results in an increase in LH and FSH levels. If applied 
continuously, these hormones are down regulated due to a negative feedback mechanism taking 
place in the gonadal-pituitary-hypothalamic axis and a following receptor down regulation 
[132] [133].  
 Therapeutic regimen and pharmaceutical products  
Estrogens and gestagens 
Altrenogest, also referred to as allyl trenbolone, is the gestagen mainly used for estrus 
synchronization in swine. It is usually fed in amounts of 15-20 mg per day over a time period 
of 14-18 d [111] [113] [117]. Besides, also norgestomet, a gestagen used in goats for estrus 
synchronization [121]. Melengestrol acetate is used in postpartum beef cattle and heifers in 
combination with prostaglandin derivatives to synchronize the estrus [134] [135]. 
 
GnRH and its analogues 
GnRH has a half-life of approximately 1 h in the blood plasma and is released physiologically 
in a pulsatile manner [136]. GnRH analogues, or so called “superagonists” with a higher affinity 
to GnRH receptors and a higher stability in vivo were developed [130] [137]. GnRH analogues 
are widely applied in both human and veterinary medicine for a variety of indications (Table 
1-1). Gonadorelin [6-D-Phe] is one analogue, reported to have a higher affinity to GnRH 
receptors [130]. Other related substances are buserelin, goserelin and triptorelin, which are 
indicated in human medicine for different cancer types, endometriosis and infertility [35]. 
Recently, goserelin was also tested as add-on to conventional medication to protect the ovarian 
function against aggressive chemotherapy in breast cancer in pre-menopausal females [138] 
[139]. 
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Table 1-1: Structural changes in amino acid sequence of GnRH analogues compared to GnRH 
Substance Amino acid sequence  
GnRH p-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 [133] 
G [6-D-Phe] p-Glu-His-Trp-Ser-Tyr-D-Phe-Leu-Arg-Pro-Gly-NH2 [10] 
Triptorelin p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2 [136] 
Buserelin p-Glu-His-Trp-Ser-Tyr-D-Ser (tBu)-Leu-Arg-Pro(NHEt) [35] 
Goserelin p-Glu-His-Trp-Ser-Tyr-D-Ser (tBu)-Leu-Arg-Pro(NEt)-AzaGly-NH2 [140]  
Peforelin pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 [141] 
Leuprolide p-Glu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro(NHEt) [142] 
In veterinary medicine, G [6-D-Phe] (Gonavet® Veyx, Veyx Pharma GmbH), goserelin 
(Fertilan®, Bremer Pharma) and peforelin (Maprelin®, Veyx Pharma GmbH) formulated in 
immediate releasing formulations are commonly used for a successful induction of ovulation in 
sows and gilts [123] [143] [144]. According to the professional information of Gonavet® Veyx, 
G [6-D-Phe] should be administered approx. 80 h respectively after the administration of 
PMSG or peforelin to gilts [10]. In sows, the new estrus should be induced with the application 
of PMSG 24 h after weaning. Depending on the duration of the suckling period, Gonavet®Veyx 
should be administered 56 to 80 h after peforelin or PMSG. Artificial insemination should be 
performed twice, 24-26 and 40-42 h after application of G [6-D-Phe] [10]. Furthermore, the 
application of GnRH analogues in a sustained release delivery system was successfully 
introduced into the market with the implant Suprelorin® (Virbac) leading to a chemical 
castration in male mature dogs as alternative to surgical castration [14] [145]. 
Beta-human chorionic gonadotropin (β-hCG) and equine chorionic gonadotrophin (eCG)/ 
pregnant mare serum gonadotropin (PMSG) 
β-hCG, another gonadotropin, can usually be found in blood plasma of pregnant females, 
responsible for the sustaining of pregnancy [146]. ECG, also called PMSG, is obtained from 
blood of pregnant mares. It is the active compound in Fertipig® (Ceva Santé Animale) and 
Suigonan® (MSD Animal Health) in combination with hCG [147] [148]. Intergonan® (MSD 
Animal Health) contains only eCG [149]. For induction of estrus, hCG is used successfully for 
treatment of weaned sows [143]. In 1982, von Kaufmann and Holtz already reported the 
successful treatment of prepubertal gilts coming into estrus by a single injection of hCG and 
PMSG [150]. 
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Prostaglandin F2-α (PGF2-α) 
PGF2-α, a prostaglandin deriving from the metabolism of arachidonic acid, is reported to have 
positive effects on artificial insemination in swine [151] [152]. Due to local effects on the 
myometrium, they are able to enhance the success of artificial insemination (AI) by induction 
of local uterus contractions with positive effects on synchronizing the ovulation [122] [153]. 
 Problems arising from Estrus Synchronization 
Meat and milk consumption is very high in western countries and is continuously increasing in 
developing countries which makes an effective livestock breeding necessary [154]. Estrus 
synchronization by gestagens is one element to achieve this. Orlando et al. reviewed problems 
going hand in hand with high doses of gestagens getting into the ground water, as side products 
of large agricultural facilities [126]. Collecting samples from a cattle runoff in the US revealed 
high amounts of gestagens and their metabolites in the manure and dry feedlot surface soil. The 
authors assume, that excretes of large agricultural holdings play an important role in the 
environmental entry of steroid hormones reaching levels over the predicted no-effect 
concentration [127]. High steroid concentrations of up to 375 ng/l were found in the melt water 
in the neighborhood of large agricultural holdings in Wisconsin [124]. Possible harmful effects 
on reproduction are reported for the fathead minnow and zebrafish, as well as for alligators and 
frogs [124] [128] [155]–[158]. 
 Aim of the Thesis 
The present thesis was performed to develop an environmentally friendly alternative for estrus 
synchronization in swine. Treatment with gestagens is the current gold standard for estrus 
synchronization. But substantial entry into the environment has been shown and it is likely that 
gestagens negatively influence reproduction of water organisms [126] [128] [129]. This work 
should focus on the development of a delivery system for the decapeptide G [6-D-Phe], which 
is able to guarantee a sustained release over two weeks. The delivery of the peptide via 
triglyceride microparticles seems to be the best choice for our purpose based on costs and 
tolerability. The system should guarantee a drug release in an effective dose over a time period 
of 15 days, followed by a more or less immediate drop to allow the simultaneous onset of a new 
estrus in all treated animals for a fixed-time insemination program.  
Chapter Two describes the first tests to establish a spray congealing process focusing on the 
impact of melt viscosities and apparatus settings on particle size and yield. Furthermore, lipid 
microparticles are evaluated for polymorphism. 
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In Chapter Three the incorporation of model substances, like the amino acid tryptophan and 
the dipeptide aspartame with focus on yield and drug content is studied. First release 
experiments from pure triglyceride matrices and in combination with emulsifiers and sugars 
were performed. 
Chapter Four focuses on the optimization of the spray congealing process with respect to yield 
and encapsulation efficiency. Material distribution during the spray congealing process and 
evaluation of possible sources for high material loss are studied. Possibilities for the 
optimization of the process are discussed. 
In Chapter Five G [6-D-Phe]-loaded microparticles obtained via the spray congealing process 
were tested. Factors influencing the release behavior, like surface morphology, water uptake 
upon incubation and polymorphic behavior are investigated. The wettability of lipid matrices 
is determined, also in combination with surfactants, by contact angle measurements using the 
sessile-drop method. The addition of different emulsifier types at various concentrations is 
screened to achieve a release over two weeks.  
Chapter Six shows the results of a particle and drug distribution study in carcasses after 
application in the lateral neck muscles.  
Chapter Seven summarizes the results of the two performed pre-clinical studies. The first study 
focuses on the dose finding of a future delivery system by application of two different 
G [6-D-Phe] doses via two different formulations. The second study evaluates four different 
formulations using only the low dose of the first study. Treated swine are investigated 
concerning biocompatibility of the tested formulations and possible adverse reactions. Most 
important is the effect on cycle blockage and onset of follicular growth, as well as determination 
of ovulation. Furthermore, the side effect of ovulatory cysts is discussed. 
Chapter Eight describes the results of a long-term stability study performed over a 12-month 
time at 2-8, 25 and 40 °C. Microparticles are investigated concerning drug content, peptide 
stability, particle morphology and size, suspension in the reconstitution medium and release 
profile. Possible instabilities arising from the storage are explained. 
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 Abstract 
A spray congealing process for the manufacturing of solid triglyceride microparticles was to be 
developed. The instrument settings, like product flow, spray pressure and spray flow were 
evaluated with respect to their effect on particle size and yield. Spray flow was identified as the 
most important factor with a moderate effect on yield and mean particle size. An improvement 
of yield and size reduction was obtained with higher spray flow. Particles of approximately 
50 µm were obtained at 20 to 50 % yield. Upon spray congealing, the triglycerides crystallized 
in the metastable α-polymorph. Transition into the thermodynamically stable β-form could be 
achieved by an additional tempering step. 
 Introduction 
Microparticles are widely used delivery systems for both small molecules and biopharmaceutic 
drugs [1]–[3]. Polymer-based microparticles, especially based on lipids are of particular interest 
[4]–[9]. Different preparation techniques exist for lipid microparticles mainly based on 
emulsion or spray techniques [10] [11]. Molten lipids can be emulsified into an aqueous phase 
at higher temperatures forming solid, spherical microparticles upon cooling [11]. The solvent 
evaporation technique is based on an organic solution of lipid dispersed in an aqueous phase 
followed by solvent removal resulting in the formation of particles [12] [13]. The disadvantages 
of these techniques are problems arising from residual organic solvents and a high loss of water 
soluble drug due to partitioning into the aqueous phase [13]. Alternatively, a solution of lipid 
in organic solvent can be spray dried [14]. 
Spray congealing, in literature also referred to as spray cooling or spray chilling, is a process 
without the use of organic solvents characterized by the atomization of a lipid melt [15] [16]. 
Typically, the small droplets are formed by the use of internal mixing two-fluid nozzles using 
compressed air or nitrogen as spray gas [17] [18]. Depending on the lipid´s 
melting/solidification point, the droplets are sprayed into a chamber, which is kept at room 
temperature [19] or below [7]. In some cases a subsequent freeze-drying step is applied [7]. 
Alternatively, atomization of the lipid melt is performed with a Venturi effect-based wide 
pneumatic nozzle (WPN) [20]. Furthermore, by the use of an ultrasound-based system, molten 
lipid can be split up into small droplets upon contact with the sonotrode followed by 
solidification at room temperature [21]–[25]. In addition, centrifugal wheel [26] [27] and 
rotating disc atomizers [28] are described. 
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In the first steps of development of lipid-based microparticles for sustained release of 
G [6-D-Phe] by spray congealing, the influence of different process parameters in a two-fluid 
nozzle-based process was evaluated. Additionally, the use of different triglycerides was 
assessed. The results with placebo particles should form the base for the subsequent studies 
with model substances and the peptide drug. 
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 Materials and Methods 
 Materials 
Dynasan 116 (tripalmitin, D116), Dynasan 118 (tristearin, D118) and Dynasan 120 
(triarachidin, D120) were kindly provided from Cremer Oleo (Witten, Germany). The 
thickening agent aluminum stearate was supplied from Fluka (Fluka, Sigma-Aldrich, 
Taufkirchen, Germany). Ultrapure deionized water with a conductivity of less than 
0.055 µS/cm (Milli-Q Water systems, Millipore, MA, USA) was used throughout all 
experiments. Polysorbate 20 (PS 20) was purchased from Merck KGaA (Darmstadt, Germany). 
 Preparation of triglyceride microparticles by spray congealing 
 
Figure 2-1: Schematic depiction of the spray congealing equipment additionally installed on top of a B-
290 Mini spray dryer 
12 g of triglyceride was melted on a hot plate and transferred into the sample container of a 
B-290 Mini spray dryer with an additional spray chilling setup (Büchi, Flawil, Switzerland) as 
visualized in Figure 2-1 . The whole system was pre-conditioned for 1.5 hours prior to particle 
production (sample container 90 °C for D116 and 110 °C for D118 and D120, spray tower 
temperature 15 °C). The original sample container with a plane bottom by Büchi was used for 
production of microparticles. Additionally, a custom-made sample container with a coned 
bottom (tilt 13 °) to minimize material loss was tested for flow-out studies. The coned bottom 
container was made by the LMU fine mechanics department at the same dimensions as the 
original flat bottom container. The connector passage between sample container and nozzle was 
heated to 70 °C with a self-made resistance wire-based heating. The spray tower was fed with 
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pre-cooled air via an additional dehumidifier Deltatherm® LT (Deltatherm® Hirmer GmbH, 
Much, Germany). The lipid melt was sprayed using nitrogen at a pressure between 4 and 6 bar. 
A high-performance cyclone was used to separate the microparticles. Resulting microparticles 
were stored at 2-8 °C until further analysis was performed. 
 Determination of yield 
Yield was determined by weighing the product container before and after microparticle 
production. Only microparticles collected in the product container were taken into account for 
yield calculation. 
 Evaluation of the product flow using different sample containers 
The product flow into the nozzle depends on the temperature as well as viscosity of the used 
melt. D116 was used as lipid material. The valve was opened and the resulting product flow 
within 20 s collected and the flow calculated in ml/min. Both the flat bottom sample container 
as well as the coned bottom container were evaluated. 
 Determination of particle size 
Approximately 20 mg of microparticles were suspended in 10 ml of an aqueous solution of 
0.02 % PS 20. The sample was analyzed in the laser diffraction system Horiba Partica LA-950 
(Horiba, Kyoto, Japan) while stirring. 
 Investigations on polymorphic behavior using differential scanning calorimetry 
(DSC) 
Microparticles were analyzed using a Mettler DSC 821e (Mettler Toledo, Columbus, OH, 
USA). 5-15 mg were weighed into aluminum crucibles and analyzed at a heating and cooling 
rate of 10 K/min from 0 to 110 °C in two cycles against an empty crucible as reference. To 
determine polymorphic behavior upon tempering, particles were stored in glass vials at 2-8, 25 
and 45 °C for 24, 48 and 72 h, respectively.  
 Characterization of particle morphology using scanning electron microscopy 
(SEM) 
Surface characteristics of lipid microparticles were assessed by SEM using a Jeol JSM 6500-F 
SEM (Jeol, Tokyo, Japan) without additional coating at 150, 900 and 1500-fold magnification, 
after attaching on aluminum sample holders with double adhesive tape (Plano, Wetzlar, 
Germany).  
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 Results and Discussion 
 Evaluation of the product flow into the nozzle using different sample containers 
As the product flow into the nozzle depends on the used melt and temperature as well as valve 
opening, the product flow in ml/min was determined experimentally for D116 at 90 °C for both 
the flat bottom container, as well as the coned bottom container. A turnable metal screw 
controlled the flow out of the container into the nozzle. Figure 2-2 shows the product flow 
depending on the valve opening out of the sample container. 
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Figure 2-2: Product flow out of the sample container for D116 at 90 °C (mean and SD, n = 3) 
Flowing of the melt started at 0.75 turns with 0.23 ml/min (flat bottom) and 0.33 ml/min (coned 
bottom) respectively. In general, both container configurations showed a similar flow rate. At 
a valve opening of 1.75 turns, the flat container showed a deviating product flow of 5.5 ml/min 
compared to the coned bottom container with 2.6 ml/min. Increasing the valve opening to 
2.0 turns, maximum flow rates of 7.1 ml/min (flat bottom container) and 7.6 ml/min (coned 
bottom container) were reached. Thus, the flow from the sample container was only minimally 
affected of the container shape. The product flow increased almost exponentially with turning 
of the valve. 
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 Preparation of drug-free lipid microparticles by spray congealing  
Subsequently, microparticles were prepared by spray congealing using the triglycerides D116, 
D118 and D120. Table 2-1 summarizes the tested settings, as well as yields and particle sizes. 
The attempt to generate larger particles by addition of 1 % aluminum stearate via increasing the 
viscosity led to valve blockages and was not further pursued. 
  
 
 
Figure 2-3: SEM images of triglyceride microparticles based on D116 (A), D118 (B) and D120 (C) 
Particles showed a spherical shape and the use of D116 led to a flaky surface appearance 
whereas D118 and D120 particles obtained a very smooth surface (Figure 2-3). 
Spray pressure is reported to be a factor of major influence on particle characteristics in spray 
congealing [29] [30]. Yield was determined as 39.0 % (4 bar), 43.7 % (5 bar) and 42.9 % 
(6 bar). Particle size did not change upon varying the spray pressure. Thus, spray pressure did 
not have major influence on product characteristics, as the actual spray gas volume (or spray 
flow) getting into the nozzle was regulated separately. 
Another important parameter is the lipid feed rate. The feed rate was varied in a range between 
0.75 and 2.0 valve turns, corresponding to an effective product flow rate between 0.23 and 
7.1 ml/min. With application of a product flow above 3 ml/min corresponding to 1.75 turns, an 
A B 
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irregular spray cone and a high material loss at the spray tower wall could be monitored, which 
reasoned slightly lower yields. 
Table 2-1: Overview of placebo microparticle batches produced with varied apparatus settings.  
TG Spray 
pressure 
[bar] 
Temp.  
[°C] 
Spray flow 
[Normlitres/h] 
Valve 
opening 
[Turns] 
Yield 
[%] 
Mean 
particle size 
[µm] 
D116 4 90 473 0.75 39.0 40.4 (± 12.0) 
D116 6 90 473 0.75 42.9 66.7 (± 28.8) 
D116 5 90 473 0.75 43.7 40.2 (± 15.5) 
D116 5 90 473 0.75 43.7 40.2 (± 15.5) 
D116 5 90 473 1 53.2 45.1 (± 14.8) 
D116 5 90 473 1.125 51.3 42.9 (± 8.0) 
D116 5 90 473 1.25 46.0 48.5 (± 10.9) 
D116 5 90 473 1.5 43.7 40.0 (± 6.0) 
D116 5 90 473 1.75 37.8 40.8 (± 5.5) 
D116 5 90 473 2 38.3 47.4 (± 2.6) 
D116 5 90 301 1 23.3 43.3 (± 3.4) 
D116 5 90 357 1 21.1 45.6 (± 7.0) 
D116 5 90 473 1 53.2 28.9 (± 16.3) 
D116 4 90 473 1 42.2 49.3 (± 12.1) 
D118 4 110 473 1 34.6 35.5 (± 14.1) 
The spray flow, a factor with high influence on particle size, was assessed between 246 and 
473 l/h [31]. At a spray flow below 301 l/h spray congealing was not possible because of 
inadequate droplet formation. At 301 and 357 l/h, yields of 22 % with particle sizes of 
approximately 45 µm could be achieved. The increase of spray flow to 473 l/h resulted in the 
highest observed yield of about 50 % and the size of the collected particles was reduced to 
28.9 µm, indicating a more effective atomization and the formation of smaller droplets. 
Consequently, the spray congealing process was rather robust over a wide range of process 
settings. The strongest influence regarding yield and particle size was observed for the variation 
of spray flow. 
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 Evaluation of polymorphic behavior 
The lipid modification of the microparticles plays a crucial role [7] [13]. After the spray 
congealing process, D116 microparticles were present in the α-polymorph as indicated by the 
melting endotherm at 46 °C in the first and the second heating scan (Figure 2-4 A) [32]. This 
hexagonal modification with only minor and unspecific chain-chain-interactions is 
thermodynamically unstable upon storage [7] [33]–[35]. According to Lutton, it is only stable 
for several weeks at room temperature [36]. Upon further heating, the exothermic 
recrystallization to the higher melting β´-polymorph occurred [32]. This orthorhombic-arrayed 
polymorph is also metastable and not always detectable in DSC [33] [37]. Further energy led 
to the formation of the most stable β-form, which should be favored for reasons of long-term 
storage. In this triclinic modification, the carbon chains are parallel to each other with a high 
potential of interaction [33] [38]. The observed polymorphic behavior went in accordance with 
the behavior of spray congealed microparticles manufactured with different natural or synthetic 
lipids as well as lipid implants and solid lipid nanoparticles [6] [19] [39]–[42]. 
Tempering at 2-8 °C and room temperature did not lead to changes in the polymorph. 
Incubation at slightly increased temperatures induced a transition of the microparticles to the 
β-polymorph with only one single melting endotherm at 65 °C already after 24 h (Figure 2-4 
E). Storage at 45 °C, which is slightly over the distinct melting point of the α-form, induces 
crystal lattice formation to the more densely packed β-form. This tempering of the lipid matrix 
is a suitable tool to induce formation in the thermodynamically stable β-modification for higher 
stability of the drug delivery systems [32] [39] [43]. 
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Figure 2-4: Polymorphic behavior of freshly prepared D116 microparticles (A) and after 72 h stored at 
room temperature (B), after 72 h at 7 °C (C), after 24 h at 45 °C (C), after 48 h at 45 °C (D) and 72 h at 
45 °C (E). Representative heating scans are depicted of the first and second heating each. Curves are 
displaced along the ordinate for better visualization  
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 Conclusion 
It was possible to produce triglyceride microparticles by the means of spray congealing. The 
choice of sample container had no pronounced influence on the product outflow, but could 
possibly minimize material loss inside the container. The evaluation of process parameters 
showed that the process was rather robust against their variation. The apparatus settings spray 
pressure, product flow and spray flow are reported to have the highest influence, which could 
only be partly confirmed in our experiment. Low product and spray flow led to insufficient 
atomization which caused a high product loss in the spray dryer. The spray flow was evaluated 
to be the most influencing factor on particle size and yield. DSC measurements showed that 
microparticles were crystalline in the α-polymorph directly after production which did not 
change upon storage at 2-8 and 25 °C over 72 h. Storage at 45 °C induced the transformation 
to the thermodynamically stable and desirable β-form after 24 h. 
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 Abstract 
Two different hydrophilic model substances, the amino acid tryptophan and the dipeptide 
aspartame, were incorporated into spray congealed lipid microparticles as a surrogate for the 
decapeptide G [6-D-Phe]. Aspartame was lyophilized to mimic the properties of the freeze-
dried drug. The spray congealing process as well as the release behavior from the obtained 
microparticles were evaluated using different triglycerides, also in combination with release 
modifying additives, such as emulsifiers and sugars. Additionally, the influence of lipases on 
drug liberation from the particles was investigated. The addition of emulsifying agents led to 
better spray performance. A slow and incomplete release resulted for pure triglyceride 
microparticles. Using tryptophan as model substance, a release for 20 d (D116 + 5 % GMS) 
with an initial burst of less than 20 % could be achieved. The formulation of D118 + 10 % GMS 
resulted in a sustained release for 24 d, whereas the initially released drug could be kept below 
25 %. The addition of lipase to the release medium led to matrix changes visible in SEM images 
also leading to a faster release when GMS concentrations higher than 5 % were used. The 
released aspartame was different compared to tryptophan and could be controlled over approx. 
10 d by the addition of Span 40 and Span 85. 
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 Introduction 
The incorporation of drugs into biodegradable matrices for parenteral application is an 
important field within pharmaceutical research [1]–[3]. Lipid drug delivery systems, like 
microparticles [4], solid lipid nanoparticles [5] and implants [6] [7] are suitable tools to prolong 
and control the delivery of drugs. Hydrophilic proteins and peptides, like somatostatin [8], 
insulin [4], thymocartin (TP-4) [9], ovalbumin [6], bovine serum albumin [10] and lysozyme 
[11] have successfully been loaded into lipid microspheres. The spray congealing process, 
technically evaluated in the previous chapter, has been reported to be a suitable technique for 
the production of lipid microparticles [4] [10] [12]. The absence of organic solvents, high yields 
and encapsulation efficiencies are benefits arising from this technique compared to other 
emulsion-based methods [4] [9] [13].  
Widely used excipients for lipid matrices are for example solid triglycerides of different chain 
length [14]–[17] and waxes [18]. Additionally, the application of composed fats, consisting of 
mono-, di- and triglycerides in variable amounts, like Compritol® 888 ATO [19] [20] or 
Gelucire® -qualities, combining glycerides and hydrophilic polyethylene glycols [21] [22] are 
common.  
Release kinetics achieved with lipid delivery systems range from several minutes up to months 
[23] [24]. With the use of spray congealed microparticles consisting of Gelucire® 50/13 loaded 
with diclofenac a complete dissolution below 10 minutes was achieved [24]. A sustained release 
was reported in case of implants consisting of high-melting triglycerides for over three months 
[14] [25]. The modification with partial glycerides improves surface wettability, as well as 
increased matrix swelling which enables drug dissolution [22] [26]. The addition of pore-
formers, like polyethylene glycol [27] [28], sucrose [14] or trehalose [29], induces the formation 
of a connected pore network above a certain concentration. Test conditions, such as temperature 
[23] [30], addition of emulsifiers to the medium [31] [32] and the presence of lipases [33] [34] 
are important variables influencing release rates. 
As a delivery system for release of G [6-D-Phe] over a 15 days’ time frame should be 
developed, lipid microparticles produced by spray congealing were selected. The following 
study focused on the incorporation of model substances as a surrogate for the peptide drug. 
Surfactants, like monostearates, sorbitan esters and fat alcohols, as well as sugars like sucrose, 
were added to influence release rates and to adjust the formulation to the required release 
profile. Furthermore, suitable release conditions with or without the presence of lipase and a 
                                                                                          CHAPTER THREE 
 
39 
 
suitable release method were evaluated based on previously reported dialysis membrane models 
for oily suspensions and other colloidal systems [35] [36]. 
 Materials and Methods 
 Materials 
The peptide drug aspartame (ASP) was obtained from Sandoz AG, Nuremberg, Germany. The 
amino acid tryptophan (TRP) was purchased from Sigma-Aldrich (Taufkirchen, Germany). 
Triglycerides Dynasan 112 (trilaurin, D112), Dynasan 114 (trimyristin, D114), Dynasan 116 
(tripalmitin, D116) and Dynasan 118 (tristearin, D118) were kindly provided from Cremer Oleo 
(Witten, Germany). Glycerol monostearate (GMS) with a monoester content of 40-55 % was 
purchased from Caelo (Caesar & Loretz, Hilden Germany). Cetylstearyl alcohol (CSA, 
Lanette® O) and Poloxamer 188 (Lutrol® F 68) were purchased from BASF (Ludwigshafen, 
Germany). Span 40, 65 and 85 were kindly provided from Croda (Nettetal, Germany). PEG-
24-glyceryl stearate (PEG-24 GS), tradename Cutina® E 24, was a kind gift from BASF 
(Ludwigshafen, Germany). Colloidal silicium dioxide (Aerosil®) was purchased from Evonik 
Industries (Essen, Germany). Sucrose was purchased from Südzucker (Mannheim, Germany). 
Ultrapure deionized water with a conductivity of less than 0.055 µS/cm (Milli-Q Water 
systems, Millipore, MA, USA) was used for preparation of buffers in this study. Visking 
dialysis tubings with a diameter of 1.6 mm and a cut-off of 12-14 kDa for performance of 
release studies were sourced from Serva Electrophoresis GmbH (Heidelberg, Germany). 
Centrifuge tubes were purchased from VWR International GmbH (Darmstadt, Germany). Lipase 
isolated from rhizopus oryzae was purchased from Sigma-Aldrich (Taufkirchen, Germany). All 
other chemicals were of analytical grade. 
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 Lyophilization of ASP 
ASP was bulk lyophilized in a concentration of 0.5 % (w/v) on a tray without addition of further 
stabilizers using an Epsilon 2-6 D freeze dryer (Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode, Germany) and the following cycle: 
Step Ramp [°C/min] Temperature [°C] Pressure 
[Torr] 
Hold time 
[min] 
Freezing 1 -50 750 60 
Annealing 1 -20 750 240 
Freezing 1 -50 750 60 
Primary drying 0.5 -20 0.0675 2100 
Secondary 
drying 
0.1 30 0.0675 720 
 Cryogenic ball-milling of ASP 
Prior to the milling step, ASP was blended with 0.5 % (w/w) Aerosil® to enable particle 
separation during the milling process. The cryogenic milling was conducted with the Cryomill 
(Retsch® Technologies GmbH, Haan, Germany) using a stainless steel beaker and two milling 
balls with a diameter of 10 mm. A precooling time of 10 min at 5 Hz was applied, followed by 
two milling cycles of 2 min each at a frequency of 20 Hz. The milled mixture was aliquoted 
and stored at 2-8 °C until spray congealing was performed. 
 Mortar grinding of TRP for suspension in the lipid melt 
Approximately 7 g of lipid components consisting of triglycerides (D116, D118) and the 
additive (GMS or sucrose) were ground together with 130 mg (1 %) or 260 mg (2 %) TRP 
manually for 30 min using mortar and pestle without heating. The remainder of the lipid 
components (total batch volume 13 g) were added and the mixture heated up on a water bath to 
90 °C. The mixture was homogenized for 1 min using an Ultraturrax T-10 basic (IKA 
Laboratory Technology, Staufen, Germany). 
 Preparation of model substance-loaded microparticles by spray congealing 
For preparation of TRP-loaded microparticles, the lipid dispersion was filled in the sample 
container of the B-290 Mini spray dryer with additional spray chilling setup (Büchi, Flawil, 
Switzerland), which was pre-conditioned for 1.5 h prior to the production step (sample 
container 90-110 °C, spray tower temperature 15 °C). The additional equipment consisted of a 
sample container, surrounded by a bath filled with polyethylene glycol (PEG) 400, also heating 
the nozzle. The connection between nozzle and sample container was heated externally by a 
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resistance wire-based heating, generating a temperature of approximately 70 °C. The spray 
tower was fed with pre-cooled air produced by an additional dehumidifier Deltatherm® LT 
(Deltatherm® Hirmer GmbH, Much, Germany). The lipid melt was atomized using nitrogen as 
spray gas at a pressure of 6 bar and a modified nozzle with an inner diameter of 2.5 mm. 
ASP-loaded microparticles were prepared by melting lipid components and adding the milled 
ASP under high shear mixing using an Ultraturrax for 2 min. The suspension was fed into the 
sample container of the spray dryer and atomized in analogy to amino acid-loaded 
microparticles. The theoretical drug load was 1.67 %. 
 Determination of particle size 
Approximately 20 mg of microparticles were suspended in 10 ml of an aqueous solution of 
0.02 % PS 20 prior to analysis. The dispersion was analyzed using the laser diffraction system 
Horiba Partica LA-950 (Horiba, Kyoto, Japan) while stirring. 
 Characterization of particle morphology using scanning electron microscopy 
(SEM) 
Particle characteristics of lipid microparticles were assessed using a Jeol JSM-6500 F SEM 
(Jeol, Tokyo, Japan) without additional coating of the particles after attaching on aluminum 
sample holders with double adhesive tape (Plano, Wetzlar, Germany). Cross sections of 
particles were prepared by cutting the particles with the use of a surgical scalpel by hand. 
 Determination of encapsulation efficiency 
30 mg of TRP-loaded microparticles were dissolved in 2.0 ml of methylene chloride and 2.0 ml 
of PBS pH 7.4 were added. Prior to analysis of the water phase, the two-phase system was 
shaken vigorously for 5 min and let stand afterwards for another 30 min. The aqueous phase 
was analyzed using the NanoDrop 2000 spectrophotometer at 280 nm [37] (Thermo Fisher 
Scientific, Waltham, MA, USA). Each batch was extracted in triplicate. 
50 mg of ASP-loaded microparticles were dissolved in 0.5 ml of methylene chloride and the 
same amount of highly purified water was added. The mixture was incubated for 18 h on the 
GFL 3031 horizontal shaking incubator (Gesellschaft für Labortechnik, Burgwedel, Germany) 
at a temperature of 39 °C and 60 rpm. All microparticular batches were extracted in triplicate 
and measured using an Agilent UV-Vis spectrophotometer 8453 (Agilent Technologies, Santa 
Clara, CA, USA) at 258 nm [38].  
                                                                                          CHAPTER THREE 
 
42 
 
 Development of a suitable release model and evaluation of TRP and ASP release 
behavior 
For release studies of TRP-loaded microparticles 100 mg with 2 % and 200 mg with 1 % drug 
load were weighed into dialysis tubings. After addition of 0.5 ml (100 mg microparticles) or 
1.0 ml (200 mg microparticles) PBS pH 7.4 with 0.05 % NaN3 and 0.02 % Poloxamer 188, the 
tubings were closed at both ends and placed in a 15-ml centrifuge tube, release medium was 
added to a total volume of 5.0 ml. Samples were incubated on a horizontal shaker at 39 °C and 
60 rpm. Additionally, the same experiment was carried out with addition of lipase from 
rhizopus oryzae in a concentration of 1.0 U/mg microparticles (corresponding to a 
concentration of 20 or 40 U/ml, respectively) in the dialysis membrane. All release studies were 
performed in triplicate. Samples of 100 μl per time point were taken, replaced with fresh release 
medium and analyzed using a NanoDrop 2000 spectrophotometer at 280 nm. 100 mg of 
microparticles without amino acid were used as control. A solution of 1 mg/ml TRP in PBS 
was filled into the membrane as positive control to proof the permeability through the 
membrane.  
100 mg of ASP-loaded microparticles were filled in dialysis tubings and 2 ml of PBS buffer pH 
7.4 were added, tubings were closed with threads at both ends and placed in 15-ml centrifuge 
tubes. 3 ml of release medium was added and samples were treated according to TRP-loaded 
microparticles. Each sample was performed and analyzed in triplicate. Samples of 100 µl were 
taken for measurement of released drug using an Agilent spectrophotometer 8453 at a 
wavelength of 258 nm. 
 Results and Discussion 
 Preparation and characterization of model drug-loaded lipid microparticles by 
spray congealing  
All TRP-loaded batches could be sprayed successfully resulting in different yield and particle 
size (Table 3-1). An increased spray flow of 473 l/h compared to 414 l/h did not influence the 
microparticle size. Both concentrations of TRP could be sprayed without affecting yield. 
Microparticles were obtained at yields in a range between 16.8 (D116) and 29.0 % (D118) with 
particle sizes between 30.2 and 53.9 µm. Addition of GMS resulted in slightly larger particles. 
With addition of GMS, yield was not affected for D118-based microparticles, but slightly 
increased for the formulations based on D116. The emulsifier GMS is reported to enable a more 
effective encapsulation, which may result in larger particles [39]. 
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Table 3-1: Overview of TRP-loaded microparticle batches sprayed with different apparatus settings and 
with addition of GMS and sucrose 
Model 
drug 
Drug Load 
[%] (w/w) 
Spray 
Flow [l/h] 
TG  Excipient [%] Yield 
[%] 
Mean Particle 
Size [µm] 
TRP 2 414 D118 - - 29.0 30.2  
TRP 1 414 D118 GMS 5   22.9 49.7 
TRP 1 414 D118 GMS 10  22.0 42.4 
TRP 2 473 D116 - - 16.8 41.8 
TRP 2 473 D116 Sucrose  1  25.5 39.0 
TRP 2 473 D116 GMS 5  28.8 50.6 
TRP 2 473 D116 GMS 10  25.9 53.9 
The addition of sucrose as pore former resulted in an irregular spray cone and valve blockages 
and was therefore not further investigated. Figure 3-1 depicts SEM images of triglyceride-based 
microparticles loaded with TRP. Microparticles showed an overall smooth surface with small 
crystals. Cross-sections confirmed a dense, compact matrix without noticeable cavities. The 
incorporated TRP could not be visualized in contrast to other researchers [25] [40]. 
   
   
Figure 3-1: SEM images of TRP-loaded microparticles (D116: A, D, D118 + 1 % sucrose: B, E, 
D118 + 5 % GMS: C, F) 
ASP lyophilisate could not be incorporated into spray congealed microparticles. Upon 
homogenization using Ultraturrax, the viscosity of the melt increased substantially and could 
not be sprayed. For this reason, all other batches were prepared using cryomilled ASP. These 
formulations could be spray congealed successfully (Table 3-2). 
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High yield of approx. 50 % were obtained for D116 with addition of 5 and 15 % CSA achieving 
values of 50 % usable product. Span 65 and 85 caused a decrease in yield. With addition of the 
low melting triglyceride D112 only 10 % product was obtained. This effect was less 
pronounced when combinations of D112 with GMS were used. The highest product yield was 
achieved with addition of 20 % PEG-24 GS. Particle size was exemplarily measured for 
triglyceride particles with addition of two intermediate and one very lipophilic emulsifiers. A 
slightly higher particle size was observed with the use of emulsifiers with lowest HLB values 
(Span 85, HLB 1.8 [41]) as well as the production with pure triglycerides. Using emulsifiers 
with higher HLB values (Span 40 and 65), particle size slightly decreased indicating a more 
ineffective drug encapsulation [42] [43]. 
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Table 3-2: Overview of 1.67 % ASP-loaded microparticle batches (s = solid, l = liquid, ss = semi-solid); 
Three emulsifies with different HLB values were investigated concerning particle size exemplarily (data 
shown mean and SD, n = 3) 
Triglyceride Excipient [%]  Yield [%] Mean particle 
size [µm] 
D116 GMS (s) 5  37.0 - 
D116 GMS (s) 10  51.9 - 
D116 GMS (s) 15 % 38.1 - 
D116 CSA (s) 5  50.5 - 
D116 CSA (s) 15  50.3 - 
D116 Span 40 (s) 5  44.3 42.7 (± 1.6) 
D116 Span 40 (s) 10  48.1 33.3 (± 1.1) 
D116 Span 40 (s) 20  43.7 - 
D116 Span 65 (s) 5  28.9 25.0 (± 1.6) 
D116 Span 65 (s) 10  43.9 32.4 (± 2.3) 
D116 Span 65 (s) 20  42.2 21.0 (± 1.9) 
D116 Span 85 (l) 2  7.6 84.6 (± 5.0) 
D116 Span 85 (l) 5  23.9 62.5 (± 12.9) 
D116 Span 85 (l) 10  20.4 65.8 (± 27.7) 
D116 PEG-24 GS (ss) 0.7  26.3 - 
D116 PEG-24 GS (ss) 10  48.8 - 
D116 PEG-24 GS (ss) 20 % 74.3 - 
D116 D112 (s) 10  10.4 69.6 (± 3.2) 
D116 GMS/D112 (s/s) 10/5  40.4 - 
D116 GMS/D112 (s/s) 10/10  42.9 - 
D114 GMS/D112 (s/s) 10/5  39.3 - 
D114 GMS/D112 (s/s) 10/10  50.3 - 
 
 In vitro release behavior of TRP-loaded microparticles 
Figure 3-2 shows the release profiles of TRP from pure triglyceride microspheres and with 5 
or 10 % GMS. Pure triglyceride microparticles showed a very low initial burst release (≤ 10 %) 
within the first day, which was also stated by other researchers when investigating peptide and 
protein release from triglyceride microparticles and cylinders [9] [44]. A high amount of drug 
remained inside the particles and the total released drug after three weeks was about 15 %. With 
addition of 5 % GMS to D116 the burst release increased to approx. 15 %. A continuous release 
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phase followed until day 20 reaching 45 % total release. With 10 % GMS, 40 % of incorporated 
TRP was released within the first day of the study and a steady release which slowed down after 
approximately one week followed. The incorporated TRP was almost completely released. 
McCarron and co-workers also found enhanced release rates for lipid particles in combination 
with emulsifiers [45]. Penetration appears to be enhanced with the higher emulsifier content. 
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Figure 3-2: Release of TRP from D116 (A) and D118 (B) microparticles without and with 5 or 10 % 
GMS in PBS pH 7.4 (mean and SD, n = 3) 
Particles based on pure D118 exhibited an initial TRP burst of less than 15 % and total drug 
release of approx. 20 %. Addition of 5 % GMS resulted in a higher burst of around 40 %, 
followed by further release of 5-10 % until day 6. In total, about 50 % of TRP was released. 
With 10 % GMS, the initial burst was low, followed by a lag time until day 10 and a continuous 
release phase until day 24. The total amount of drug released was 45 %. The incomplete drug 
release might be due to, on the one hand, an insufficient emulsifier concentration to facilitate 
the penetration of medium into the core of the particle or the adsorption to the lipid in solution 
[8] [46]. Incorporation of cholesterol and mono- or diglycerides has been described as suitable 
means to tailor release kinetics from triglyceride matrices [26] [47]. The concentration 
dependent emulsifier effect was also shown by other researchers who found enhanced release 
of hydrophilic drugs, like diclofenac [39]. Thus, the release can be adapted by the addition of a 
W/O surfactant. 
 Influence of lipase addition to the release medium on TRP release  
Lipases are present in a variety of organs of the mammalian body and digest lipids typically by 
cleaving fatty acids from the triglyceride backbone [48]. The activity in the human body differs 
depending on the organ and is reported to be 0.01 U/ml in serum and subcutaneous fat [33]. In 
this study, the lipase concentration was set at 20 U/ml to see the effect during the 20 day-study 
period more clearly. 
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Figure 3-3: Release of TRP from D116 (A) and D118 (B) microparticles with 0, 5 and 10 % GMS in 
PBS pH 7.4 containing 40 U/ml lipase (mean and SD, n = 3)  
Lipase addition resulted in slightly enhanced drug release from D116-based microparticles 
(Figure 3-3). Compared to the release in PBS buffer, the burst was increased by about 10 % 
and a continuous release could be monitored until day 11. In total, 25 % of incorporated drug 
were released, approximately 10 % more than in absence of lipase. For D116 particles with 
GMS, a general trend to a faster release could not be stated. Slightly enhanced release profiles 
could be observed regarding the pure triglyceride formulation and the combination with 5 % 
GMS. The most pronounced effect was noticed for microparticles formed with 10 % GMS. A 
burst of 40 % was followed by a continuous drug release until the end of the monitored time. 
The addition of higher amounts of monostearates enhanced the digestion. Surface structure was 
affected by the presence of lipase (Figure 3-4). Whereas microparticles in absence of lipase 
kept the initially observed smooth surface with slightly increased roughness potentially due to 
swelling [26], particle surface became uneven with larger flaky structures [47] and a more 
porous surface [33] [49] in presence of lipase. Keeping the lipase activity in the body in mind, 
the effect of lipase in vivo is most likely only minimal. 
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Figure 3-4: D118 + 5 % GMS-based microparticles after 3-weeks incubation in PBS pH 7.4 without 
lipase (A) and with 40 U/ml lipase (B) 
 Evaluation of lipid composition and additive concentration on in vitro release 
behavior of ASP from lipid-based microparticles 
In addition to the release of TRP, particles containing the dipeptide ASP were tested. Figure 
3-5 shows selected ASP release profiles. Specifically, the influence of surfactants as release 
modifiers has been studied [50]. Vilivalam and Adeyeye showed, that the addition of stearic 
acid led to an enhanced release of diclofenac from waxy microspheres [39]. Furthermore, the 
hydrophilic and lipophilic properties of the drug influence the ability to be released from the 
matrix. More hydrophilic drugs are dissolved easier out of a lipid matrix than more lipophilic 
ones [20]. We studied the effect of both W/O or O/W-emulsifiers on the release behavior.  
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Figure 3-5: Release of ASP from D114 and D116 microparticles blended with emulsifying additives 
and/or low melting triglycerides in PBS pH 7.4 (mean and SD, n = 3) 
The addition of GMS to D116 did not result in an improved release profile but only a burst of 
15-25 % without further release. The use of CSA with a lower HLB value showed a comparable 
effect at both tested concentrations as a sustained release profile could not be obtained. To 
achieve a more complete ASP release, combinations of GMS and D112 were tested using the 
base lipids D116 and D114. Again, the desired profile could not be obtained. PEG-24 GS, an 
O/W emulsifier, led to a more complete drug release at higher concentrations, but did not render 
a sustained release profile. Khan and co-workers investigated the Gelucire® family, consisting 
of glycerides in combination with PEG-esters. Depending on the composition, a swelling and 
enhanced water penetration could be achieved leading to a faster drug release [51]. 
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Most promising results could be obtained with the use of sorbitan fatty acid esters. Span 40, 
with an HLB value of 6.7 [41], resulted in promising profiles with a release up to 10 d when 
added in concentrations of 5 and 10 % to D116. 5 and 10 % Span 85, with an HLB value of 1.8 
[41] rendered a sustained release profile for 12 d with an initial burst of 15 and 30 % 
respectively for the 5 and 10 %-addition. Thus, with ASP as model compound, no adequate 
release profile over 15 d could be achieved. Comparing the TRP and ASP release profiles led 
to the assumption, that the release behavior of G [6-D-Phe] is hard to predict. Drug properties 
appear to play an important role. Having been able to find the required release profile using 
TRP in a triglyceride formulation using GMS, this approach seemed most suitable for 
G [6-D-Phe]. An addition of Span 40 and 85 could form a promising base for further 
development. 
 Conclusion 
The spray congealing process was determined as suitable production process for the preparation 
of TRP- and ASP-loaded microparticles. In general, microparticles with a spherical shape and 
smooth surface could be produced. Variation of process parameters did not result in pronounced 
changes regarding yield and particle size, confirming an adequate robustness of the process. 
Exclusive use of triglycerides D116 and D118 did not result in adequate release profiles, as a 
preferably low burst was not followed by a sustained release. With addition of 5 and 10 % GMS 
to D116 and D118, release profiles over 20 d could be obtained for TRP. The addition of lipases 
to the release medium led to a slightly accelerated and more complete release, but the enzymatic 
degradation is expected to have little influence in vivo. None of the tested formulations using 
ASP as model substance showed the aspired release profile. In most of the cases, a continuous 
release could not be observed. Formulations which could provide a springboard for the 
following study using G [6-D-Phe] could be based on D116 and D118 with 10 % GMS. 
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 Abstract 
The spray congealing process was evaluated concerning material loss, yield, particle size of 
different fractions deposited in the spray dryer and drug load using aspartame as model 
substance. The apparatus settings spray flow, aspirator power, melt temperature and installation 
of an additional stirrer were varied. Viscosities of lipid melts were determined using a rotational 
viscometer. Viscosity was mainly influenced by the temperature of the melt and only marginally 
by the lipid composition. At a spray flow of 414 l/h, a product yield of approximately 25 % 
resulted with substantial material loss in the spray tower and the melt container. Other 
components like high-performance cyclone, filter and connection between spray tower and 
cyclone were not identified as critical parts. Increasing the spray flow to 601 l/h resulted in 
higher product yield of approx. 45 % whereas a decrease in spray flow to 301 l/h and a reduction 
of the aspirator capacity reduced the yield. Melt temperature reduction (yield approx. 40 %) 
and installation of a stirrer within the sample container (yield approx. 50 %) had positive effects 
on product yield. Mean particle size changed with spray flow, from 70 (301 l/h) over 45 
(414 l/h) to 20.7 µm (601 l/h). Highest encapsulation efficiencies in the product could be 
achieved with reduction of the spray flow to 301 l/h, as well as with the reduction of the melt 
temperature from 90 to 75 °C. 
 Introduction 
The spray congealing process is a widely used technique suitable for encapsulation of drugs 
[1]–[3]. Having been able to develop a method suitable for the encapsulation of the amino acid 
tryptophan as well as the dipeptide aspartame, the process and influencing parameters should 
be further investigated. A lot of experimental data and knowledge is available on the influence 
of different nozzle types on the process and the product, but only little research has been done 
with the focus on yield distribution and material loss [4]–[7]. Particle size is typically influenced 
by spray flow and temperature difference between the melt and tower [8]. In general, for the 
spray congealing process rather high yields are reported [4], [9]–[11]. Additionally, the drug 
load depends on the apparatus settings. In general it is stated, that a faster solidification of 
microparticles leads to a desirably high entrapment efficiency [12] [13].  
This chapter deals with the adjustment of the process with focus on the reduction of material 
loss, improvement of yield, a homogenous drug distribution within the melt, as well as particle 
sizes adequate for veterinary i.m. injection. 
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 Materials and Methods 
 Materials 
Triglycerides Dynasan 114 (trimyristin, D114) and Dynasan 116 (tripalmitin, D116) were 
kindly provided from Cremer Oleo (Witten, Germany). Aspartame (ASP) was purchased from 
Sandoz AG (Nuremberg, Germany). Glycerol monostearate (GMS) with a monoester content 
of 40-55 % was supplied from Caelo (Caesar & Loretz GmbH, Hilden, Germany). Colloidal 
silicium dioxide (Aerosil®) was purchased from Evonik (Hanau, Germany). Sorbitan 
monopalmitate (Span 40) was purchased from Croda (Nettetal, Germany). Polysorbate 20 
(PS 20) was supplied from Merck KGaA (Darmstadt, Germany). All other chemicals were of 
analytical grade. 
 Cryogenic milling of ASP 
ASP was blended with 0.5 % of colloidal silicium dioxide prior to being loaded into stainless 
steel milling beakers of the Cryomill (Retsch® Technologies GmbH, Haan, Germany). The 
powder was milled using two stainless steel milling balls with a diameter of 10 mm. A 
precooling time of 10 min at 5 Hz was followed by the actual milling step for 2 x 2 min at 
20 Hz. 
 Preparation of triglyceride-based microparticles by spray congealing 
Lipid components were melted on a hot plate, 100 mg (0.83 % drug load) or 200 mg (1.67 % 
drug load) ASP were added and homogenized using a T-10 basic Ultraturrax (IKA, Staufen, 
Germany) for 2 min (total batch volume 12 g). The melt was transferred into the sample 
container of the B-290 Mini spray dryer with additional spray chilling setup (Büchi, Flawil, 
Switzerland), which was pre-conditioned for 1.5 hours prior to the production step (sample 
container 75-90 °C, spray tower 15 °C), monitored with a PeakTech infrared thermometer 
(PeakTech Prüf- und Messtechnik GmbH, Ahrensburg, Germany). A modified nozzle with an 
inner diameter of 2.5 mm was used to avoid nozzle blockages. The connecting passage between 
sample container and nozzle was heated with a resistance wire-based heating to 70 °C. The 
spray tower was fed with pre-cooled air produced via an additional dehumidifier Deltatherm® 
LT (Deltatherm® Hirmer GmbH, Much, Germany). The lipid melt was sprayed using nitrogen 
at a pressure of 6 bar. A high-performance cyclone was used to separate the microparticles.  
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 Determination of material distribution in the spray dryer 
The formulation D116 + 5 % Span 40 with an ASP load of 0.83 % was sprayed as described in 
4.3.3. After the manufacturing process, the dryer was dismounted and the solidified material 
removed using a flexible soft rubber scraper. High-performance cyclone and filter were 
weighed before and after the experiment. Sampling points are depicted in Figure 4-1. 
 
Figure 4-1: Schematic plan of the spray dryer. Particles were sampled at (1) sample container, (2) spray 
tower, (3) spray tower vessel, (4) connection, (5) high-performance cyclone, (6) product container and 
(7) filter 
 Determination of particle size 
Approximately 20 mg of microparticles were suspended in 10 ml of an aqueous solution of 
0.02 % PS 20 and analyzed using the laser diffraction system Horiba Partica LA-950 (Horiba, 
Kyoto, Japan).  
 Determination of encapsulation efficiency 
Depending on theoretical drug load, 50 or 100 mg microparticles were dissolved in 1.0 ml of 
methylene chloride and the same amount of water was added. The tubes were incubated 
overnight on a horizontal shaker GFL 3031 (Gesellschaft für Labortechnik, Burgwedel, 
Germany) at a temperature of 39 °C at 60 rpm. Each sample was extracted in triplicate and 
measured using an Agilent Spectrophotometer 8453 (Agilent Technologies, Santa, Clara, CA, 
USA) at a wavelength of 258 nm [14]. 
1 
2 
3 
4 
5 
6 
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 Determination of lipid-melt viscosities 
An MCR 100 rheometer (Physica, Anton Paar, Ostfildern, Germany) was used for 
determination of viscosity of the melt using the cone/plate method and the CP-50 1 
measurement system at a logarithmic shear rate from 1-100 s-1. The plate was preheated at the 
desired temperature of 75 or 90 °C.  
 Results and Discussion 
 Viscosity of the lipid melt 
The viscosity of lipid melts can have an influence on the properties of the spray congealed solid 
lipid microparticles and the process [6] [9] [15]. In particular particle size of the generated 
spheres [4] [16], yield [9] and their time for solidification [17] are affected. Recently, Wong et 
al. investigated the temperature-dependent viscosity of lipids suitable for spray congealing, and 
revealed that viscosity of the melt decreases up to a certain temperature, above which the 
viscosity does not decrease any more with further heating [15]. Furthermore, the viscosity of 
triglyceride melts increases with longer side chains [18]. Consequently, the viscosities of 
differently formulated lipid melts at 75 and 90 °C were tested. D114 and D116-based 
formulations with addition of 5-10 % GMS and Span 40 showed viscosities between 10 and 
25 mPas measured at 90 °C. With temperature reduction to 75 °C the viscosity slightly 
increased to 35 mPas (Figure 4-2), according to literature [15] [19]. When spraying was 
performed under a certain temperature, an increase in particle size upon spray congealing can 
be observed [15]. Formulation effects on the melt viscosity were not detectable during our 
experiments. Higher viscosities compared to pure lipid melts, as well as shear thinning are 
reported in literature for lipid suspensions [20]. 
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Figure 4-2: Viscosity of drug-free lipid melts (D116 and D114) with emulsifiers at 90 °C and 75 °C at 
a shear rate of 1 s-1 (Mean and SD, n = 2) 
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 Yield distribution and material loss during the spray congealing process  
Due to low yields of 20 to 50 % in the previously performed spray congealing experiments, it 
was necessary to evaluate where the high material loss occurred. Other researchers reported 
yields of over 90 % with the use of spray congealing [4] [9] [21]. With the standard conditions 
(inlet temperature 90 °C, spray pressure 6 bar, aspirator 100 %, spray flow 414 l/h) a yield of 
26 % was exemplarily achieved during implementation of our spray congealing process (Figure 
4-3 A). Highest material loss occurred in the spray tower itself (49 %), whereas only 1 % ended 
directly in the spray tower vessel. The material found in the tower was not completely solidified 
when getting in contact with the glassware. Another critical part for material loss is the sample 
container. Having a plane bottom and being construed for volumes of up to 300 ml [22], the 
container is prone for residual melt remaining inside when working with smaller batches. All 
other parts, like the connection, the high-performance cyclone, as well as the filter did not have 
a critical influence on material loss. A low material loss in the cyclone was also reported by 
Scott et al. [6].  
The aspirator, generally responsible for drying of particles, is known to influence total batch 
yield in spray drying [23] [24]. The speed with which the droplets follow the airstream 
determines their contact time with the tempered air and thus the drying or solidification [25]. 
Reduction of aspirator power from 100 to 70 % led to a marginally reduced yield as observed 
with spray-dried insulin [26]. The material found in the spray tower was reduced to 36 %, 
whereas the particle amount found in the spray tower vessel increased. Obviously, the reduced 
aspirator force enabled a more effective solidification in the tower. Thus, the amount usually 
found in the spray tower was transferred to the spray tower vessel, also confirming the theory 
of a more effective solidification. Other parts of the spray dryer were only of minor importance 
(Figure 4-3 B).  
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Figure 4-3: Material distribution after spray congealing experiments using standard conditions (spray 
flow 401 l/h, aspirator 100 %, 90 °C) (A), reduced aspirator power of 70 % (B), reduced spray flow of 
301 l/h (C), increased spray flow of 601 l/h (D), melt temperature 75 °C (E) and installation of an 
additional stirrer (F). “Others” includes filter, high-performance cyclone and connection tube between 
tower and high-performance cyclone  
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An important factor in both spray drying and congealing is the spray flow, responsible for the 
effectiveness in atomization [27]. Reduction of spray flow to 301 l/h led to a remarkable 
reduction in product yield (Figure 4-3). Material loss in the spray tower was increased to about 
60 %, whereas more than 8 % of the powder were found in the spray tower vessel, indicating 
the formation of larger droplets and incomplete solidification. Also, a high amount of residual 
lipid material was found in the sample container. Application of higher spray flow of 601 l/h 
resulted in an increased product yield of 45 %. Compared to standard conditions, the material 
lost in the spray tower was reduced to approximately 6 % and about 16 % of the material could 
be collected from the spray tower vessel. Surprisingly, again a high residual melt could be found 
in the sample container. A higher spray flow causes the formation of smaller droplets, which 
solidify more rapidly [9] [28]. Reduction of spray flow led to larger spheres, which could be 
responsible for lower yields, due to insufficient hardening and collision with the tower wall. 
Furthermore, larger spheres generated at lower spray flow values may not be able to follow the 
air stream [29]. 
Another approach to influence spray properties is the modification of the melt viscosity by 
changing the temperature (Figure 4-3 E) [4] [15]. A higher product yield of 41 % was reached 
with a reduction of the melt temperature from 90 to 75 °C. The amount collected in the spray 
tower could be reduced to approx. 6 %, due to a more effective solidification, as the temperature 
difference between liquid and solid state of the lipid was reduced. This also caused a higher 
amount of solidified product in the spray tower vessel. As a downside, a higher amount of 
residual melt of about 27.35 % resulted.  
For an effective and homogenous spray congealing process an additional stirring device was 
installed. The stirrer led to an increase in product yield to about 51 %. Moreover, the material 
lost in the spray tower could be reduced to approx. 9 %, whereas the material collected in the 
spray tower vessel was increased to about 31 %. The residual melt could be minimized by the 
stirrer to approx. 6 %, as less material gathered at the sample container. 
The tested parameters showed that material loss in spray congealing was sensitive to production 
parameters. Substantial loss of material could be noticed in the spray tower, as well as in the 
sample container. The most positive effect resulted from an increase of spray flow to 601 l/h 
and the installation of an additional stirrer.  
  
                                                                                            CHAPTER FOUR 
 
64 
 
 Investigations on particle size of drug-loaded particles 
Particle size is another critical parameter in the development of a spray congealing process. The 
size of the generated spheres affects drug release and encapsulation capacity [30] [31]. For this 
reason, particle fractions from the spray tower, spray tower vessel and product container were 
collected and analyzed for mean particle size (Figure 4-4).  
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Figure 4-4: Mean particle size of samples collected in the product container (A), spray tower vessel (B) 
and spray tower (C). Standard settings were defined as spray flow 414 l/h, spray pressure 6 bar, aspirator 
100 %, melt temperature 90 °C (black arrows) 
Most important was the particle size of the product. The largest particles (> 65 µm) were formed 
at a reduced spray flow of 301 l/h. When applying standard spray flow of 414 l/h the achieved 
particles were about 45 µm in diameter. Increase of spray flow to 601 l/h led to reduction of the 
particle size to approx. 23 µm. This effect was reported for both spray drying and spray 
congealing processes [9] [27] [32] [33]. Besides the product, also the particles found in the 
spray tower and the spray tower vessel were affected by the spray flow, with larger particles 
found at a reduced spray flow. The reduction of aspirator power affected the size of the particles 
collected in the product and spray tower vessel only marginally, in contrast to Esposito et al. 
during spray drying. A remarkable increase in size of the particles from the tower was observed. 
These observations might be explained by a longer residence time in the airstream, which allow 
the solidification of larger droplets [25]. Thus, a possible reduced deposition of droplets on the 
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chamber wall can be achieved. Nevertheless, product size was barely affected. Generally, the 
product showed a smaller diameter compared to fractions collected in the spray tower and spray 
tower vessel. Due to their bigger size, particles were not able to follow the airstream and were 
deposited in the spray tower vessel. 
A reduction of the melt temperature did not lead to an increase in particle size of the product, 
but the particle size of material collected from both the spray tower and the spray tower vessel 
was substantially reduced to under 100 µm. 
The installation of an additional stirrer slightly reduced the product particle size to approx. 
30 µm. Particles collected in the spray tower showed a reduced particle size, whereas the 
particles in the spray tower vessel were larger. These findings indicate that the additional 
vibration of the stirrer caused a slightly inhomogeneous atomization. 
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 Evaluation of drug distribution and encapsulation efficiency 
Ideally, the final product should show an encapsulation efficiency of 100 %. Commonly, high 
encapsulation efficiencies are reported for spray congealed delivery systems, especially in 
comparison to emulsion-based methods, where problems in drug encapsulation occur due to 
migration into the aqueous phase [9] [11] [34] [35]. 
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Figure 4-5: Drug loads of collected samples from the product container (A), spray tower (B) and spray 
tower vessel (C). Standard settings were defined as spray flow 414 l/h, spray pressure 6 bar, aspirator 
100 %, melt temperature 90 °C (black arrows) 
The application of standard conditions (Figure 4-5 A) led to an encapsulation efficiency of 38 % 
in the product and higher values of 45-60 % were obtained in the spray tower and spray tower 
vessel. Reducing the spray flow to 301 l/h resulted in a considerable increase in drug load to 
80 %, which might go in accordance with the simultaneous increase in particle size, possibly 
enabling a better encapsulation [31] [36]. Spheres collected from the spray tower and vessel 
were not affected. Applying a spray flow of 601 l/h reduced the drug load in all sampled 
fractions. The reduction of aspirator capacity to 70 or 80 % respectively, affected drug 
encapsulation only marginally.  
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Melt temperature reduction to 75 instead of 90 °C increased the loading efficiency compared 
to standard conditions in the product as well as in the material collected in the spray tower 
vessel and the spray tower. The expectation of achieving better results with the installation of 
an additional stirrer were not fulfilled, all three fractions showed drug loads below 40 %. 
In brief, with variation of apparatus settings it was possible to influence particle size and 
encapsulation efficiency to a certain extent. Generally, the spray congealing process can be 
regarded as complex process, with a variety of parameters having an influence. The reduction 
of spray flow was a suitable means to increase particle size, which also had positive effects on 
the encapsulation efficiency. On the other hand, an increase of spray flow affected the drug 
content negatively, due to the decreased particle size. Acceptable results concerning particle 
size and encapsulation efficiencies could be reached with the reduction of the melt temperature. 
Particle size remained constant with slightly enhanced encapsulation efficiencies in all sampled 
fractions. The installation of a vibrating stirrer led to opposite effects as expected, as an 
inhomogeneous atomization resulted and the product showed less encapsulated drug. The 
aspirator capacity did not affect the particle size and encapsulation efficiency substantially. 
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 Conclusion 
The spray congealing process was investigated concerning yield and material distribution, 
particle size and encapsulation efficiency. The parameters spray flow, aspirator power, melt 
temperature, as well as the influence of an additional stirring device were evaluated. Our 
investigations showed, that the highest material loss can be found in the spray tower, spray 
tower vessel as well as in the sample container. Filter, high performance cyclone and the 
connection between tower and cyclone were not evaluated as critical parts for material loss. 
The most pronounced effect on yield of the useable product could be determined by the increase 
of the spray flow to 601 l/h and by the melt temperature reduction to 75 °C. All other variations 
led to lower yields and a higher material loss. Evaluating particle size of the product, the 
variation of spray flow was determined as the most influencing factor. Drug distribution, which 
was an issue during previously performed experiments, could be improved by the reduction of 
melt temperature to 75 °C, as well as the reduction of spray flow. Viscosity measurements 
revealed, that the melt temperature was the mainly influencing factor, indicating that the 
decrease in melt temperature to 75 °C resulted in increased viscosity. Overall, the spray 
congealing process is influenced by a variety of parameters. Our results showed, that an increase 
in particle size is going hand in hand with a better encapsulation efficiency, which can be 
achieved by the reduction of spray flow. The increase in spray flow implemented the formation 
of smaller particles with considerably lower drug loadings. Increasing viscosity by the means 
of temperature reduction increased encapsulation efficiency due to faster solidification. Thus, 
a compromise needs to be found to assure an acceptable drug loading and process yields. 
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 Abstract 
The decapeptide gonadorelin [6-D-Phe] was incorporated into spray congealed microparticles 
consisting of triglycerides of different chain lengths. As a continuous release in the desired time 
frame of 15 d could not be achieved with the exclusive use of triglycerides, different additives 
like GMS, CSA and Spans were applied to modify the release behavior. To investigate the 
underlying mechanisms influencing the release profile, polymorphic behavior, surface 
morphology and wettability, as well as water uptake were investigated. Crystallization of the 
α- or β-form and entrance of water were determined to be influenced by the emulsifier type and 
its concentration. Wettability of lipid surfaces was low regarding pure triglycerides and was 
increased when surfactants, especially monoglycerides, were added to the formulation. SEM 
images showed a particle breakdown upon incubation when liquid emulsifiers were used. It was 
possible to achieve a sustained release for 14 and 22 d with the addition of 10 % GMS to D116 
and D118. Release duration of 20 d was obtained with the addition of 5 % Span 40 to D114. 
Thus, two formulations for subsequent in vivo studies in swine could be identified. The 
challenge of a high burst release could be minimized by suspending the particles in a 
thermosensitive poloxamer-based gel.  
 
  
                                                                                             CHAPTER FIVE 
 
74 
 
 Introduction 
The treatment with peptides or proteins often comes with frequent injection [1]–[4]. This can 
be a problem and limitation for application in human and as well veterinary medicine, due to 
compliance, efforts and cost issues compared to orally applied small molecule drugs. To 
circumvent these problems, sustained release systems for peptides and proteins are sought after 
[5]–[12].  
One example for an immediate releasing biopharmaceutical formulation in veterinary use is 
Virbagen® Omega (Virbac), delivering interferon omega for the feline immunodeficiency virus 
(FIV) and feline leukemia virus (FeLV) in cats, as well as parvovirus in dogs [13]–[16]. 
Furthermore, GnRH-analogues are currently used for induction of ovulation in swine, cattle and 
mares [17]–[20]. Gonadorelin [6-D-Phe] (G [6-D-Phe]), active compound in Gonavet®Veyx 
(Veyx Pharma GmbH) with a molecular weight of 1000 Da, is a GnRH (LHRH)-I agonist with 
a higher affinity to GnRH receptors [21]–[24]. Other commonly used GnRH analogues for 
estrus control are buserelin (Receptal®, MSD Animal Health) [25] [26], lecirelin (Dalmarelin®, 
Fatro) [27] and peforelin (Maprelin®, Veyx Pharma GmbH) [28]. Besides the veterinary 
importance, GnRH analogues are used in several indications in humans, for example breast and 
prostate cancer, endometriosis and fertility disorders [29] [30].  
In 1985, one approach for a sustained delivery was the application of nafarelin, a substance 
related to GnRH-I for estrus suppression in female dogs, via an osmotic pump system [12]. 
Current, sustained release delivery systems used in veterinary medicine are injectable 
suspensions, solid implants, in-situ forming implants and microparticles mostly based on lipid 
compounds [12] [31] [32] [33]. Lipid excipients inherit several advantages compared to other 
polymers, as biodegradability, high biocompatibility and low costs [34] [35]. 
The lipid-based implant Suprelorin® (Virbac), containing deslorelin acetate, is approved for the 
non-invasive castration in male dogs [36] [37]. The implant consists mainly of hydrogenated 
palm oil and is biodegradable, which omits surgical removal [37]. Besides the use in male dogs, 
a deslorelin-containing implant was also tested in female dogs [36] and was able to achieve a 
suppression of estrus for 27 months [38].  
Estrogen and progesterone-loaded, polymer-based microparticles have been investigated in 
terms of estrus synchronization in mares [39]. Additionally, ProHeart® 6 (Zoetis) is a 
microparticular delivery system based on tristearin for the antibiotic substance moxidectin, 
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which has the FDA approval in the USA  and provides a 6-month protection against the canine 
heartworm disease [32] [40] [41].  
Consequently, we developed an injectable sustained release system based on triglyceride 
microparticles for G [6-D-Phe] via spray congealing. The incorporation of the drug G [6-D-Phe] 
and the adaption of the process was the focus of this work. Additionally, the in vitro release of 
G [6-D-Phe] was to be investigated to achieve a sustained release over  two weeks suitable for 
estrus synchronization in swine [42]. In order to understand the underlying release mechanism, 
lipid polymorphism, surface wettability and water uptake were evaluated.  
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 Materials and Methods 
 Materials 
Lyophilized G [6-D-Phe] was donated by Veyx Pharma GmbH (Schwarzenborn, Germany). 
Triglycerides Dynasan 114 (trimyristin, D114), Dynasan 116 (tripalmitin, D116) and Dynasan 
118 (tristearin, D118) were kindly provided from Cremer Oleo (Witten, Germany). Glycerol 
monostearate (GMS) with a monoester content of 40-55 % was purchased from Caelo 
(Caesar & Loretz, Hilden, Germany). Cetylstearyl alcohol (CSA, Lanette® O) was purchased 
from BASF (Ludwigshafen, Germany). Span 40, 60, 80, 85 were kindly provided from Croda 
(Nettetal, Germany). Poloxamer 407 and Hydranal® for Karl-Fischer titration were purchased 
from Sigma-Aldrich (Taufkirchen, Germany). Ultrapure deionized water with a conductivity of 
less than 0.055 µS/cm (Milli-Q Water systems, Millipore, MA, USA) was used throughout all 
experiments. Centrifuge tubes were purchased from VWR International GmbH (Darmstadt, 
Germany). Visking dialysis tubings with a diameter of 1.6 mm and a cut-off of 12-14 kDa for 
performance of release studies were sourced from Serva Electrophoresis GmbH (Heidelberg, 
Germany). All other chemicals were of analytical grade.  
 Cryogenic milling of G [6-D-Phe] 
G [6-D-Phe] was milled using a Retsch® Cryomill (Retsch Technology, Haan, Germany) 
equipped with two stainless steel milling balls (diameter 10 mm) with a precooling time of 
10 min at 5 Hz followed by the actual milling step of 4 min at 20 Hz. The obtained powder was 
aliquoted under nitrogen atmosphere. 
 Preparation of G [6-D-Phe]-loaded microparticles by spray congealing 
Lipid compounds were melted on a hot plate at 90 °C, the peptide was added and homogenized 
using a T-10 basic Ultraturrax (IKA Laboratory Technology, Staufen, Germany) for 2 min. A 
Büchi B-290 Mini spray dryer (Büchi, Flawil, Switzerland) with additional spray chilling setup, 
was pre-conditioned for 1.5 hours prior to the production step (sample container 90 °C/110 °C, 
spray tower 13-15 °C). Additional equipment consisted of a sample container surrounded by a 
polyethylene glycol (PEG) 400 bath. The connection between sample container and nozzle was 
heated externally by a resistance wire-based heating to approximately 70 °C. The spray tower 
was fed with pre-cooled air produced by an additional dehumidifier Deltatherm® LT 
(Deltatherm® Hirmer GmbH, Much, Germany). The lipid melt was filled into the sample 
container and sprayed using nitrogen and a modified nozzle with a channel diameter of 2.5 mm 
using the following apparatus settings: 
                                                                                             CHAPTER FIVE 
 
77 
 
Spray parameter Value 
Spray pressure [bar] 6 
Aspirator power [%] 100 
Valve opening [turns] 1.25-1.5  
Temperature oil bath [°C] 90 (D114, D116), 110 (D118) 
Inlet temperature [°C] 13-17 
Pressure filter [mbar] 92  
Spray flow [l/h] 414  
All produced microparticle batches had a theoretical drug loading of 1.8 %. 
 Determination of particle size 
20 mg of microparticles were suspended in 10 ml of an aqueous solution of 0.02 % PS 20 and 
measured with the laser diffraction system Horiba Partica LA-950 (Horiba, Kyoto, Japan). 
 Investigations on polymorphic behavior using differential scanning calorimetry 
(DSC) 
Microparticles, triglycerides and lipid mixtures were analyzed using a Mettler DSC 821e 
(Mettler Toledo, Columbus, OH, USA). 5-15 mg sample were weighed into aluminum 
crucibles and analyzed at a heating and cooling rate of 10 K/min between 0 °C to 110 °C in two 
cycles. Incubated particles were dried on a lint-free cloth for 1 h at room temperature. 
 X-Ray powder diffraction (XRPD) of lipid microparticles 
XRPD measurements were conducted with 2 different systems: 
• Small sample quantities were analyzed with a PANalytical Empyrean (PANalytical, 
Almelo, the Netherlands) equipped with a copper anode (45 kV, 40 mA, Kα1 emission 
λ = 0.154 nm) and a PIXcel3D detector between 5 to 50 ° 2-Theta with a step of 0.039 °. 
• To analyze multiple samples and to benefit from an autosampler, samples were scanned 
between 10 and 40 ° 2-Theta at a step size of 0.05 ° with a XRD 3000 TT (Seifert, 
Ahrensburg, Germany) equipped with a copper anode (λ= 0.15418 nm, 40 kV, 30 mA). 
  
                                                                                             CHAPTER FIVE 
 
78 
 
 Karl-Fischer titration 
10 mg microparticles were weighed into 2 R glass vials, closed with rubber stoppers and 
analyzed with an Aqua 40.00 titrator (Analytik Jena, Jena, Germany) with a headspace module 
at 100 °C. The analysis of incubated particles in PBS was performed after drying on a lint-free 
cloth for 1 h at room temperature.  
 Characterization of particle morphology using scanning electron microscopy 
(SEM) 
A Jeol JSM 6500-F SEM (Jeol, Tokyo, Japan) was used for SEM-images at a voltage of 2 kV. 
Microparticles were fixed on aluminum sample holders with black, double adhesive tape 
(Plano, Wetzlar, Germany) and analyzed without an additional graphite coating. After release 
studies, particles were washed five times and dried for 48 h in a vacuum dryer (Memmert 
GmbH, Schwabach, Germany) at 25 mbar and 25 °C. 
 Contact-angle measurements for prediction of lipid surface wettability 
Contact angle measurements were performed using the Krüss Drop Shape Analyzer DSA 25 
(Krüss, Hamburg, Germany). 0.5 g of lipid components were melted at 80 °C, poured onto glass 
microscopy slides and cooled for solidification. A drop volume of 2 µl water was placed on the 
lipid surface at a speed of 1 ml/s. Measurements were performed in triplicate after a wait time 
of 20 s (mean values of left and right contact angle). The ellipse-tangent-1 fit was used for 
calculation of contact angles. 
 Determination of drug-content using RP-HPLC after extraction 
20 mg microparticles were weighed into 30 ml-centrifuge tubes, dissolved in 2.0 ml of 
methylene chloride and the same amount of water was added. The tubes were placed on a 
horizontal shaking incubator GFL 3031 (Gesellschaft für Labortechnik, Burgwedel, Germany) 
at 39 °C for 12 h. Samples of 1 ml were taken from the water phase and analyzed using RP-
HPLC. Extractions were performed in triplicate. RP-HPLC analysis was performed using an 
Agilent RP-HPLC system (Agilent, Santa Clara, CA, USA), supplied with a 250 x 4.6 mm Luna 
(5 µm) C-8 column (Phenomenex, Aschaffenburg, Germany) and a SecurityGuard KJO-4282 
C-8 pre-column (5 µm) (Phenomenex, Aschaffenburg, Germany). Columns were maintained at 
40 °C using the following gradient: 
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Time [min] A [%] B [%] 
0 65 35 
1 65 35 
21 65 35 
22 10 90 
26 10 90 
35 65 35 
Mobile Phase A: 1000 ml highly purified water + 1 ml trifluoracetic acid  
Mobile Phase B: 800 g Acetonitrile + 200 g water + 1.2 ml trifluoracetic acid 
 In vitro release behavior of G [6-D-Phe] from lipid microparticles 
Approximately 50 mg of microparticles were transferred into dialysis tubings, 2.0 ml of 
phosphate-buffered saline (PBS) pH 7.4 preserved with 0.05 % NaN3 were added, followed by 
the addition of glass balls which served as additional weight. The closed tubings were placed 
in 50 ml centrifuge tubes, 15 ml PBS were added and incubated on a horizontal shaking 
incubator at 39 °C and 60 rpm. When poloxamer gels were used as suspension medium, the 
centrifuge tubes were pre-filled with PBS and incubated overnight at 39 °C. Dialysis tubings 
with an aliquot of microparticles and 2 ml of poloxamer gels were closed and put into pre-
heated surrounding buffer. At predetermined time points, samples of 1 ml volume were taken 
and removed solution was replaced by fresh PBS. Samples were analyzed with RP-HPLC as 
described in 5.3.10.  
 Preparation of poloxamer gels 
Poloxamer 407 (Sigma-Aldrich, Taufkirchen, Germany) was dissolved in water in a refrigerator 
at 2-8 °C overnight. 
 Temperature-dependent viscosity measurements using a rotation viscometer 
For analysis of temperature-dependent gelling behavior, an MCR 100 rheometer (Physica 
Anton Paar, Ostfildern, Germany) with a plate/plate system PP-25 and a temperature ramp from 
4 to 34 °C was used at a shear stress of 1 Pa. Each measurement was performed in triplicate. 
  
                                                                                             CHAPTER FIVE 
 
80 
 
 Results and Discussion 
 Preparation of drug-loaded lipid microparticles by spray congealing  
Based on previous spray congealing tests with placebo and model substance-loaded 
microparticles, a first set of spray congealing conditions and formulations for G [6-D-Phe] was 
selected (Table 5-1). Initial criteria for the performed pre-tests were yield, particle size and 
encapsulation efficiency (EE).  
Table 5-1: First generation G [6-D-Phe]-loaded formulations produced by spray congealing 
TG Additive Concentration [%] Yield [%] EE [%] 
D 118 - - 13.8 61.3 
D 116 - - 20.6 56.7 
D 118 GMS 10  17.8 61.4 
D 118 GMS 20  16.6 40.4 
D 118 GMS 40  3.1 15.9 
D 118 GMS 60  4.9 23.5 
D116 GMS 10  26.1 38.9 
D116 GMS 20  30.6 37.0 
D116 GMS 40  21.0 41.0 
GMS - - ≤ 1 23.5 
D116 CSA 10  32.3 47.1 
D116 CSA 20  19.1 56.8 
D116 CSA 60  26.6 54.8 
G [6-D-Phe]-loaded microparticles could be sprayed in analogy to placebo and model 
substance-loaded particles. Compared to the incorporation of model substances, the peptide led 
to a more persistent and continuous spray cone and less valve blockages. The use of pure GMS 
resulted in needle-like, inadequate particles, which showed pronounced electrical charging. All 
other batches showed higher yields. Pure triglyceride formulations showed yields below 21 % 
and GMS addition led to slightly increased product yields. More than 30 % product could be 
obtained with 10-20 % GMS. Generally, obtained yields were lower as reported in literature 
[43] [44] [45], since we only considered the powder in the product vessel.  
EE was about 60 % for pure triglycerides. The addition of 10 % GMS to D118 led to 
comparable results whereas EE was slightly decreased when added to D116. With higher 
amounts of monoglycerides added to D118 the drug load decreased. The addition of higher 
amounts of GMS and CSA to D116-based microparticles did not affect the drug load, which 
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went in accordance with data reported by Eustáquio Matos-Jr. et al. comparing hydrogenated 
palm oil and glycerol monostearate particles [45].  
Table 5-2: Second generation G [6-D-Phe]-loaded formulations produced by spray congealing 
TG Additive  Concentration [%] Yield [%] EE [%] 
D114 GMS 10 % 33.9 78.4 
D114 GMS 5 % 22.7 78.7 
D114 Span40 5 % 28.8 51.2 
D114 Span 40 10 % 12.1 21.1 
D114 Span 40 30 % 1.6 n.d. 
D114 Span 85 10 % 17.8 60.9 
D114 Span 85 20 % 16.2 46.5 
D114 Span 80 10 % 2.1 57.4 
D114 Span 80 20 % 16.4 21.9 
D114 Span 85 30 % 3.4 21.1 
D116 Span 85 10 % 15.9 71.9 
D116 Span 85 20 % 17.8 72.4 
D116 Span 85 30 % 7.6 71.4 
D116 D112 10 % 7.9 81.8 
D116 Span 40 5 % 15.6 29.9 
D116 Span 40/D112 10 % 4.1 14.4 
D116 GMS/ D112 5 %/10 % 22.88 64.34 
D116 GMS/ D112 10 %/10 % 18.22 65.30 
D116 Span 80 10 % 7.27 40.15 
D116 Span 80 30 % 10.59 43.56 
Second generation of lipid microparticles was produced using short-chain triglycerides and a 
broader spectrum of surfactants to achieve a faster release [46]. D114 rendered adequate yields 
between 23 and 34 % upon spray congealing in combination with 5 and 10 % GMS, 
respectively. The encapsulation efficiency was raised to 79 %. The addition of Span 40 with a 
HLB value of 6.7 [47] [48] caused an irregular spray cone due to the formation of foam, also 
reasoning lower yields and decreased EE. The use of surfactants with lower HLB-values, Span 
80 and 85 [47], also reduced process yield. EE was acceptable (71 %) when Span 85 was used 
in combination with D116 and reduced when combined with D114 (21-60 %). Span 80 led to 
lower EE. D112 was previously used as low melting component in the manufacturing of solid 
lipid implants, where a faster degradation rate was obtained [49] [50]. A lower yield but 
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acceptable EE of 81.75 % was achieved. Triple combination of D112 with GMS and Span 40 
resulted in appropriate results regarding GMS, but both reduced yield and drug content when 
Span 40 was added.  
Sprayability, yield and EE are critical parameters in the production of spray congealed lipid 
microparticles. The parameters yield and EE seemed to be influenced by the concentration and 
state of emulsifier, also affecting solubility of the drug in the lipid [51]. In general, for spray 
congealed lipid microparticles high yields and encapsulation efficiencies above 90 % are 
reported in literature, which could not be achieved during our experiments [44] [52]. No 
pronounced effects regarding EE were found by Mccarron et al., comparing different 
emulsifier-triglyceride compositions [53]. Possible approaches to enhance EE were achieved 
by addition of Aerosil® and a followed increased viscosity [54], bigger particle sizes [55] and 
higher drug-lipid ratio [56]. 
 Characterization of polymorphic behavior using DSC and XPRD 
The polymorphic behavior of the microparticles was analyzed by DSC and XRPD. The heating 
curve of D116 showed a melting endotherm with an onset of 42 °C corresponding to the α-
polymorph [57] followed by an exothermic recrystallization and subsequent melting of the 
thermodynamically stable β-polymorph (Figure 5-1) [58]. Particles with 5 % Span 40 showed 
similar trace. A single sharp peak corresponding to the β-form could be observed when Span 
85, GMS or the lower melting D112 were added. The small endotherm at 45 °C for 
microparticles of 80 % D116, 10 % D112 and 10 % GMS was either due to melting of D112 or 
the α-polymorph of D116 [57] [59]. For pure GMS, polymorphic transformation is also known 
with the α-polymorph melting at 67.9 °C and β-polymorph at 71.9 °C [60]. An event in this 
temperature region could not be detected in the GMS-containing microparticles. 
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Figure 5-1: DSC thermograms of G [6-D-Phe]-loaded microparticles (n = 2). Thermograms represent 
the first heating scan of one sample exemplarily and were shifted on the ordinate for better visualization 
The addition of 5 and 10 % Span 40, 80 and 85 to D114 resulted in crystallization of the 
thermodynamically stable β-polymorph with a melting onset of 53 °C and a melting peak of 
55-58 °C [61] [62]. The instable α-form with a melting point of 32 °C [62] was not detected in 
any sample. Whittam and Rosano observed that the transformation to the β-modification was 
already completed after 31 min at room temperature [62]. 
To further investigate the crystallization behavior of lipids, DSC measurements were conducted 
after incubation in PBS. D114-based samples showed the β-polymorph with a melting 
temperature of 57 °C [58] [63] after incubation, irrespective of the additive. D116-based 
microspheres with addition of GMS/D112 showed a small endotherm at 46 °C [64] prior to 
incubation. Upon incubation, re-crystallization to the β-polymorph melting at 60 °C occurred, 
which is a slightly lower melting point compared to literature [62]. Furthermore, a wider peak 
was observed. When Span 85 was added, no changes were observed. 
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Figure 5-2: Representative DSC thermograms of G [6-D-Phe]-loaded triglyceride microparticles before 
and after incubation (4 h, 24 h, n = 3) in PBS buffer pH 7.4 at 39 °C. Scans were shifted on the ordinate 
for better visualization 
XRPD measurements were conducted to further investigate the polymorphs (Figure 5-3). D114 
raw material showed the characteristic triglyceride pattern of the β-polymorph with three peaks 
at 18, 22 and 23 ° 2-Theta [65]. This pattern was also visible upon analysis of spray congealed 
particles of D114 with 10 % Span 40 and D114 + 5 % GMS. GMS raw material revealed two 
peaks at 18 and 24 ° 2-Theta also indicating the β-polymorph [66]. D116 raw material showed 
the peaks of the stable β-modification [65]. Microparticles with 5 % Span 40 addition as well 
as pure Span 40 showed one single peak at 21 ° 2-Theta, confirming a different crystal structure 
[57]. In contrast, D116 microparticles with 10 % Span 85 clearly exhibited the β-polymorph. 
As already indicated in DSC measurements, crystallization of the stable modification was not 
completed in the microparticle formulation D116 + 10 % GMS/10 % D112.  
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Figure 5-3. Representative XRPD measurements of lipid raw materials and spray congealed lipid 
microparticles (n = 3). Diffraction patterns were shifted on the ordinate for better visualization 
Crystallization behavior of lipid-based delivery systems is influenced by a variety of exogenic 
factors, especially when manufactured at higher temperatures. Underlying principles are not yet 
fully understood. In our study, the crystallizing polymorph depended on the used triglyceride 
itself, as well as the emulsifier. The delay or promotion of crystallization in the 
thermodynamically most stable β-form depends on the ability of the emulsifier to interact with 
the crystal lattice of the lipid [67]. D114 with its shorter fatty acid side chains seemed to have 
an enhanced property to crystallize in the β-polymorph upon spray congealing, irrespective of 
the emulsifier. D116 showed a partial complete formation of the α-polymorph in combination 
with 5 % Span 40, as well as in combination with GMS and D112 which indicates a stabilization 
of α-crystal lattice with these emulsifiers. 
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 Dependency of water uptake of G [6-D-Phe]-loaded microparticles from the lipid 
composition 
To evaluate moisture of freshly prepared particles and their water uptake, the produced 
formulations were investigated by the means of Karl-Fischer titration. Water uptake between 3 
and 30 % was reported for triglyceride cylinders depending on cholesterol content over six 
months [68]. For triglyceride implants, a water uptake of maximum 10 % depending on the 
chain length could be demonstrated [69]. The higher water uptake of microspheres compared 
to cylinders can be explained by a higher surface to volume ratio [68]. Investigations on 
Gelucire® 50/13 tablets revealed that a continuous water uptake over 8 h to more than 80 % was 
possible [70]. In our case, particles showed an initial water content between 0.05 % 
(D114 + 10 % GMS) and 0.19 % (D114 + 20 % Span 80, Figure 5-4) after production. 
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Figure 5-4: Water content of spray congealed microparticles consisting of D114 with different 
emulsifying additives (mean and SD, n = 3) 
After 24 h of incubation, water content of D116-based microparticles with Span 40 and 85 
stayed below 3 % (Figure 5-5). A higher water uptake between 10 and 30 % was found when 
D114 was combined with Span 80 and 85. A water content below 10 % was obtained with 5 % 
Span 40, whereas the combination of 10 % Span 40 with D112 increased the incorporated water 
to more than 40 %. Vogelhuber et al. identified the chain length of triglycerides as possible tool 
for swelling and release modification [68]. Addition of GMS to D114 led to an increased water 
uptake, whereas 5 % GMS addition did not enhance water penetration. In general, D114-based 
microparticles showed higher water uptake especially in combination with liquid and low 
melting emulsifiers compared to D116 microparticles. 
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Figure 5-5: Water uptake of spray congealed lipid microparticles after incubation in PBS at 39 °C 
determined by Karl-Fischer titration (mean and SD, n = 3)  
 Impact of lipid-composition on contact angle and surface wettability  
To understand release behavior from lipid matrices, surface wettability can be a helpful tool 
[71] [72]. In our case, the preparation of flat lipid surfaces was possible with all lipid mixtures. 
Figure 5-6 shows the contact angle of highly purified water on formulations based only on 
mono- or triglycerides. Resulting contact angles are complex results of different influencing 
factors, like surface roughness and surface tension [72]–[74]. The highest contact angle of 114 ° 
was observed for the triglyceride with the shortest fatty acid chain, D114. Tripalmitin (D116), 
tristearin (D118) and triarachidin (D120) showed lower contact angles and following better 
wettability. Glycerol monostearate showed the best wettability with a contact angle below 90 °. 
Koennings et al. found out, that wettability of lipid matrices decreases with increasing chain 
lengths [72]. This trend could not be observed in our experiments. One reason might be, that 
the lipid was not casted out of an organic solution on the microscopy slide to achieve similar 
conditions and contraction behavior compared to the spray congealing process. This procedure 
seemed suitable for our purpose, as the surface structure and the crystallization behavior affect 
wettability [75]. This was also suggested by Del Curto et al., who reported improved wettability 
of co-melted particles compared to those prepared by solvent-stripping [4]. 
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Figure 5-6: Contact angle of highly purified water on triglycerides (D114, D116, D118, D120) and 
GMS (mean and SD, n = 3) 
Figure 5-7 shows the contact angles of D114-emulsifier mixtures. GMS addition led to 
improved wettability at 10 %, whereas the contact angle was increased at only 5 %. 
Concentrations above 20 % Span 40 and 10-20 % Span 80 reduced the contact angle 
dramatically. No pronounced effect was visible for a Span 85 addition. 
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Figure 5-7: Contact angle of highly purified water on D114-emulsifier mixtures (mean and SD, n = 3) 
Replacing D114 by D116, no pronounced effect on contact angles was observed in combination 
with 5 % Span 40 and 10 % D112 (Figure 5-8). A stepwise reduction was found when using 
Span 85. Formulation with the low melting triglyceride D112, the contact angle was raised to 
123.61 °. A remarkable reduction in contact angle was observed using GMS and Span 60 as 
well as Span 85 in higher concentrations. 
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Figure 5-8: Contact angle of highly purified water on D116-emulsifier mixtures (mean and SD, n = 3) 
Admixing emulsifiers to triglycerides led to enhanced wettability depending on type of 
triglyceride and emulsifier type and its concentration. Surface roughness and the so called 
“blooming” of triglycerides needs to be taken into account, when investigating the wettability 
of lipid surfaces. The smooth surfaces reported for the α-modification [76] are known to obtain 
increased wettability compared to those of the platelet- or flake-like surface of the β-polymorph 
[77] [78]. Consequently, polymorphic transformations need to be taken into consideration, as 
we showed that crystallization behavior also depended on emulsifier-triglyceride composition. 
 In vitro release behavior of G [6-D-Phe] from lipid microparticles 
Microparticles based on pure D116 and D118 were investigated concerning their G [6-D-Phe] 
release behavior. In both cases a low burst between 10 and 25 % resulted, followed by only 
minimal release within the subsequent two weeks (Figure 5-9), according to literature [2]. This 
goes in line with the fact that the pure triglyceride microparticles do not take up substantial 
amounts of water and G [6-D-Phe] only dissolves at the surface. Comparable release profiles 
from lipid microparticles were observed for desmopressin [79] [80]. Additionally, the used 
theoretical drug load of 1.8 % was insufficient to form a connected pore network. In literature, 
drug loads above 10 % are reported for implants to be sufficient for a formation of connected 
pores and to achieve sustained protein release [81].  
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Figure 5-9: G [6-D-Phe] release from triglyceride microparticles (D116 solid line, D118 dashed line; 
mean and SD, n = 3) 
To enhance peptide release, combinations of triglycerides with non-ionic emulsifiers were 
tested. Glycerol mono- and distearate have been reported to enhance peptide release from lipid 
microspheres [46] [79]. Figure 5-10 gives an overview on the influence of a CSA- and GMS-
addition to triglycerides on G [6-D-Phe] release. The addition of CSA to D116 led to an 
increased burst compared to pure D116 already at 10 %. Increasing the CSA content above 
20 %, about 85 % of the drug were already released as burst. Microparticles prepared from 
10 % GMS and 90 % triglyceride exhibited a high burst release of 55 %, followed by a 
continuing release until day 14. In total, 70 % of the incorporated drug was released. With 20 % 
GMS, the burst release was comparable and the sustained release could be monitored until day 
12. An immediate release was obtained when 40 % GMS were added. 
SEM micrographs of freshly prepared D118 microparticles with 10 % GMS showed particular 
shape before and after incubation, with increased roughness after incubation, indicating 
possible matrix changes like “blooming” (Figure 5-11) [78].  
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Figure 5-10: G [6-D-Phe] release from triglyceride microparticles with varied amounts of CSA (10, 20, 
40 %) (A). G [6-D-Phe] release from D116 (B) and D118 (C) microparticles with varied concentrations 
of GMS (10 %, 20 %, 40 %, 60 %), mean and SD, n = 3 
The use of D118 with 10 and 20 % GMS was most promising, resulting in a burst release 
between 45 and 60 % and a continuous release over 14 to 22 d releasing more than 80 % of the 
incorporated drug. Further increase of GMS did not lead to a sustained release profile, possibly 
due to a monoglyceride-induced matrix instability (Figure 5-10 C) [79]. Incomplete drug 
release (only 80-90 %) is frequently observed for lipid-based drug delivery systems [82], 
possibly due to an incomplete water accessibility of the core [83] [84] or an adsorption to matrix 
material [80] [85].  
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D118 + 10 % GMS 
  
Figure 5-11: SEM images of freshly prepared microparticles of D118 + 10 % GMS (left) and after a 4-
week incubation in PBS at 39 °C (right) 
To generate particles with a shorter release than 22 d additional mixtures of triglycerides with 
emulsifiers were tested. Therefore, a variety of emulsifying substances with different HLB-
values were introduced. Furthermore, the low melting lipid D112 was added to enhance release 
rates as reported for solid lipid implants [49]. Figure 5-12 gives an overview on release behavior 
of screened batches. 
Having achieved adequate results with the combination of D116 with GMS, this additive was 
tested in combination with D114. Release from D114 microparticles with as well 5 and 10 % 
GMS was completed after 3 d releasing 70 % to 90 %. SEM images revealed that the GMS-
containing microparticles still remained their shape (Figure 5-13 exemplarily shows data of 
D114 + 10 % GMS). An increased roughness upon incubation could be observed, indicating 
swelling of the matrix followed by an enhanced porosity and water uptake [68] [86]. 
The addition of the liquid emulsifiers Span 80 and 85 with low HLB values did not show 
concentration dependent effects. The faster and more complete release could be explained by 
the liquid state of Span 85 leading to a faster drug liberation and complete degradation of the 
microparticles, independent of the added concentration as visualized by SEM images (Figure 
5-13 exemplarily shows D114 + 20 % Span 85). Overall, an almost complete drug release could 
be observed in all three tested formulations.  
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Figure 5-12: G [6-D-Phe] release from D114 microparticles with addition of Span 40 and GMS (A) and 
Span 80 and 85 (B), D116 microparticles with addition of Span 85 (C) and Span 80 (D) and with addition 
of D112/GMS and D112 (E), mean and SD, n = 3 
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The addition of Span 85 to D116 instead of D114 resulted in almost complete drug release 
within one day, whereas the particles were stable over two weeks exemplarily shown for 
D116 + 30 % Span 85 (Figure 5-13). Addition of Span 60 and 80 (Figure 5-12 D), as well as 
the combination of GMS and D112 (E) also resulted in a high burst release of 80 to 100 % from 
D116 microparticles. Only in case of the Span 60 containing microparticles the high burst 
release could be explained by complete disintegration of the matrix. The other combinations 
resulted in microparticles which kept their shape. 
Adequate release until day 20 could be observed for D114 microparticles with 5 % Span 40. 
Using D116 as base lipid, release was limited to 9 days. (Figure 5-12 C). Both particle qualities 
remained intact (Figure 5-13). A G [6-D-Phe] fraction remained inside the particles due to 
insufficient interconnectivity of pores. The development of a rougher surface upon incubation 
reflects the enhanced water uptake into the core of the microparticles [83].  
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D116 + 30 % Span 80 
  
D116 + 10 % GMS/ 
10 % D112 
  
Figure 5-13: SEM images of freshly prepared (left) and incubated D114 and D116-based particles with 
addition of Span 40, 60, 80, 85, GMS and D112 for 2 weeks in PBS buffer at 39 °C (right) 
Consequently, pure triglyceride matrices did not lead to appropriate release profiles as they do 
not allow substantial water uptake. Furthermore, the drug load is low and thus an interconnected 
pore network cannot form upon drug dissolution. Thus, the addition of surfactants plays a major 
role [84] [87]. Mixing emulsifying agents with triglyceride base materials led in general to an 
enhanced drug release. Some emulsifiers like Span 40, GMS and CSA showed concentration 
dependent effects. GMS is reported to either retard [83] [84] or enhance drug release [82] [88] 
from lipid-based microparticles. We noticed the latter in our study. 
Furthermore, the parameters wettability, polymorphic state as well as surface structure seem to 
influence the release behavior. In some test formulations, we noticed particle breakdown as a 
consequence of good wettability (D114 + 10 % Span 60). In other formulations, the particle 
collapsed despite insufficient wettability (D114 + 10 % Span 85), indicating that incubation 
time and temperature caused the mechanical breakdown.  
Crystallization processes occurring in lipid matrices upon accelerated temperatures are reported 
to influence release behavior [67] [75] [78]. It is not fully understood, whether the polymorph 
itself or the rearrangements of the crystal lattice are responsible for changes in drug liberation 
[44] [78]. The influence of the polymorphic state on release could be explained by different 
mechanisms. On the one hand, the less densely packed hexagonal α-modification may lead to 
an enhanced drug release compared to the more dense, triclinic β-form [44] [89]. On the other 
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hand, structural changes upon re-crystallization like blooming, are supposed to influence the 
drug release [78]. An appropriate release profile could be found throughout the study in 
microparticles crystallizing in either α- or β-modification. As shown for the D116, GMS and 
D112-composed particles upon incubation at 39 °C, a transition to the stable polymorph is 
enabled. Appropriate release profiles over two weeks could be achieved in vitro with 
microparticles containing either 10 % GMS or 5 % Span 40. These particles kept their shape 
and had the ability to take up adequate amounts of water.  
The ideal candidate for a potential sustained release delivery system for G [6-D-Phe] should 
guarantee a sustained peptide release of 15 days to ensure cycle blockage in gilts. Based on this 
requirement, in the first pre-clinical study we focused on the D116 and D118 formulations with 
10 % GMS which provided an in vitro release over 22 days with a high burst (Figure 5-14 A). 
Taking the presence of lipases in the mammalian body [90] [91] and a possibly higher 
degradation rate of the lipid microspheres, body movement and temperature into account, a 
longer in vitro release than 15 d may result in a promising in vivo effect [50] [92]. 
0 2 4 6 8 10 12 14 16 18 20 22
0
10
20
30
40
50
60
70
80
90
100
G
 [
6
-D
-P
h
e
] 
R
e
le
a
s
e
 [
%
]
Time [d]
 D116 + 10 % GMS
 D118 + 10 % GMS
 
0 2 4 6 8 10 12 14 16 18 20 22
0
10
20
30
40
50
60
70
80
90
G
 [
6
-D
-P
h
e
] 
R
e
le
a
s
e
 [
%
]
Time [d]
 D114 + 5 % Span 40
 D114 + 10 % Span 40
 D114 + 10 % GMS
 D116 + 5 % Span 40
 
Figure 5-14: Identified candidates for clinical studies. (A) Suitable microparticle batches based on 
D116 and D118 with 10 % GMS applied in pre-clinical study I (September 2014). (B) Formulations 
prepared of D114 and D116 with different amounts of Span 40 and GMS used in pre-clinical study II 
(August 2015) 
In the second pre-clinical study, microparticles with a faster release based on the combination 
of D114 with 5 and 10 % Span 40, 10 % GMS as well as D116 + 5 % Span 40 were evaluated 
(Figure 5-14 B).  
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 G [6-D-Phe] release from lipid-based microparticles suspended in thermosensitive 
poloxamer gels 
In order to cope with the problem of a high initial burst, suspensions of microparticles in a 
thermosensitive poloxamer-based gel were evaluated. Wenzel et al. reported the delivery of 
deslorelin and GnRH in a thermosensitive poloxamer gel assuring delayed plasma peak levels 
for the gel compared to the solution after injection in cattle [93].  
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Figure 5-15: Viscosity measurements of PG in water (A) and PBS pH 7.4 (B) using a temperature ramp 
from 4 to 34 °C (mean and SD, n = 3) 
Viscosity measurements revealed a temperature-dependent gelling behavior controlled by 
poloxamer concentration, whereas gelling showed an earlier onset when PBS was used (15 % 
poloxamer 407, Figure 5-15) confirming findings from literature [94]. The formulation should 
show a low viscosity at ambient temperature for application and a rapid gelling when brought 
into the tissue. Thus, formulations with 18 and 20 % poloxamer 407 were thought not feasible 
for our purpose, as they already showed an increased viscosity at 24 °C and 20 °C. Kempwade 
et al. found gelling temperatures of 32-34 °C for 18 % and 26 °C for 20 % poloxamer gels [95]. 
Compared to the aqueous solution of G [6-D-Phe], the release through the gel was delayed. 
According to other studies, the in vitro release from poloxamer 407 gels is rather short in a 
range of a few days [96]. 80 % of rIL-2 was released within 8 h from a poloxamer 407 gel in 
vitro [97]. The prolonged release of G [6-D-Phe] from the gel observed in our study may be 
caused by protection of the gel from dissolution by the dialysis tubing and the incubation 
temperature of 39 °C [98] [99]. As free fatty acids are reported to enhance mechanical strength 
of poloxamer gels, possible interactions with lipid microparticles and surfactants cannot be 
excluded [94]. 
The initial burst of microparticles could be reduced compared to suspension in PBS. 
D114 + 5 % Span 40 did not reveal a reduced burst, but an overall decelerated release (Figure 
5-16).  
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Figure 5-16: Release profiles of G [6-D-Phe] dissolved in water and PG 16 % (A) and drug-loaded 
microparticles after suspension in thermosensitive poloxamer gels (PG) with concentrations of 14 and 
16 % (B-E) mean and SD, n = 3 
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 Conclusion 
The aim of this chapter was to investigate whether it is possible to incorporate G [6-D-Phe] into 
lipid-based microparticles to achieve a continuous release over 15 days, as required for estrus 
synchronization. Based on previous results with hydrophilic model substances, different 
triglycerides and surfactants were tested concerning in vitro release behavior, wettability of the 
lipid matrix as well as particle morphology before and after incubation. The use of pure 
triglycerides did not result in appropriate release behavior. The addition of release modifying 
substances was mandatory. With addition of emulsifiers it was possible to tailor the release 
kinetics concerning burst and completeness of drug release. With the use of GMS and Span 40 
it was possible to achieve a release duration of 22 (D118) and 20 d (D114). The burst release 
could be reduced by the use of suspensions of triglyceride microparticles in thermosensitive 
poloxamer gels.  
To understand the underlying release mechanisms from lipid-based microspheres, DSC and 
XRPD measurements gave an insight into the crystallized polymorph. In addition, Karl-Fischer 
titration showed that water uptake and swelling behavior of triglyceride matrices could not be 
generalized for surfactant type or HLB-value and was more pronounced for short-chain 
triglycerides in combination with liquid emulsifiers. Surface wettability of triglyceride matrices 
was insufficient and could mostly be improved by addition of surfactants. The combination of 
different triglycerides resulted in higher contact angles compared to the individual triglyceride 
formulation. 
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 Abstract 
In order to understand the distribution behavior of spray congealed lipid microparticles, dye-
loaded microparticles were injected after suspension in a hydrophilic solvent into the neck or 
caudal thigh muscles of swine carcasses. The injection was performed using 2-ml syringes with 
16 or 18 G needles and with an injection revolver for the application of multiple units. The 
aqueous resuspension medium spread rapidly, confirmed by ultrasound as well as opening the 
injection site by incision. The microparticles could be found at the injection site upon incision. 
With the help of ultrasound, it was not possible to detect the microparticles in the muscle. 
 Introduction 
Microparticulate drug delivery systems are typically applied subcutaneously or intramuscularly 
[1] [2]. Aiming mostly for a systemic effect with a controlled or delayed release [3]–[5], it is 
important to investigate the distribution of microparticles after injection. This includes whether 
the microparticles are enclosed by a fibrous capsule, and if a local inflammatory reaction or 
transport takes place in vivo [6] [7]. A general problem arising from a depot formation may be 
a high local concentration of the residual drug [8]–[11]. The injection of depot formulations 
may also impair meat quality at the injection site on food producing animals [12]. The use of 
biodegradable microspheres or liposomes may minimize tissue lesions in food producing 
animals [11] [10]. 
Our purpose was the development of a delivery system, which is able to control the release of 
the peptide Gonadorelin [6-D-Phe] in the porcine muscle tissue and which is easy to inject. The 
reconstituted microparticles are intended for application via a syringe with a 16 or 18 G needle, 
but for a more effective injection for multiple animals, the use of an injection-revolver should 
be preferred. This device is commonly used for veterinary products with a higher importance 
of multiple-dose delivery systems, also mirrored in a variety of patents [13]–[15]. 
Consequently, the distribution of microparticles was to be studied in carcasses in order to 
understand the spreading behavior and to gain a preliminary insight into suspension 
performance in the injection device for the upcoming pre-clinical studies. Additionally, using 
the dye-loaded microparticles, the dye distribution in the surrounding tissue was to be assessed.  
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 Materials and Methods 
 Materials 
Methylene blue and crystal violet, as well as polysorbate 20 (PS 20) were purchased from 
Merck KGaA (Darmstadt, Germany). Dynasan 116 (tripalmitin, D116) was kindly provided 
from Cremer Oleo (Witten, Germany). The gelling agent Tylopur® C 300 (sodium 
carboxymethylcellulose, Na CMC) was kindly donated from Clariant (Muttenz, Switzerland). 
The suspended microparticles were applied via a 2-ml syringe equipped with a 16 or 18 G-
needle (B. Braun Melsungen AG, Melsungen, Germany) or an injection revolver HSW ECO-
MATIC® (Henke Sass Wolf GmbH, Tuttlingen, Germany) with an injection volume of 2.0 ml. 
The needle used in this study had a length of 40 mm and a diameter of 2 mm. 
Two swine carcasses used in this study were fully mature German Landrace x Piétrain and were 
kindly donated by the Faculty of veterinary medicine of the University of Leipzig. 
 Preparation of dye loaded lipid microparticles by spray congealing 
For preparation of 1 % dye-loaded microparticles, the lipid dispersion was filled in the sample 
container of the B-290 Mini spray dryer with additional spray chilling setup (Büchi, Flawil, 
Switzerland), which was pre-conditioned for 1.5 h prior to the production step. The additional 
equipment consisted of a sample container, surrounded by a bath filled with polyethylene glycol 
(PEG) 400, also heating the nozzle. The connection between nozzle and sample container was 
heated externally by a resistance wire-based heating, generating a temperature of approximately 
70 °C. The spray tower was fed with pre-cooled air produced by an additional dehumidifier 
Deltatherm® LT (Deltatherm® Hirmer GmbH, Much, Germany). Lipid melt was sprayed using 
nitrogen as spray gas and the following apparatus settings: 
Spray-parameter Value 
Spray pressure [bar] 5 
Spray flow [l/h] 357 
Aspirator power [%] 100 
Valve opening 1.25 turns 
Temperature oil bath [°C] 90  
Inlet temperature [°C] 15 
Pressure filter [mbar] 96  
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The produced lipid microparticles were separated using the high-performance cyclone from 
Büchi and stored at 2-8 °C. 
 Scanning Electron Microscopy 
A Jeol JSM 6500-F SEM (Jeol, Tokyo, Japan) was used at 2 kV. Particles were fixed on 
aluminum sample holders with double adhesive tape (Plano, Wetzlar, Germany) and were 
analyzed without an additional graphite coating. 
 Preparation of the reconstitution medium  
Na CMC was added to an aqueous 0.02 % PS 20 solution under stirring in concentrations of 
0.5, 1.0 and 2.0 % (m/V) until a clear solution was obtained.  
 Application of microparticles 
Approximately 50 mg of microparticles were mixed with 7 ml of reconstitution medium and 
shaken until a homogenous suspension was obtained. For ultrasound investigations, it was tried 
to visualize the microparticles in a higher concentration by suspension of 50 mg in 4 ml of the 
reconstitution medium. 2 ml of the suspension were injected into the lateral neck 
(m. rhomboideus cervices, m. rhomboideus capitis, m. semispinalis capitis, m. complexus, 
m. serratus ventralis cervices) or caudal thigh muscles (m. biceps femoris, m. semitendinosus, 
m. semimembranosus) via a 2-ml syringe using a 16/18 G needle or the injection revolver. The 
muscle tissues were examined concerning visibility of a bolus, distribution of hydrophilic color 
and localization of the microparticles. Ultrasonographic examination was performed using an 
esaote myLab ultrasonic device (Esaote Biomedica Deutschland GmbH, Köln, Germany).  
Additionally, the injection sites were examined surgically. Therefore, the skin was cut 
crosswise with a scalpel. The cross-section was carefully held open to examine and to document 
the color of the spreading dye and the localization of the microparticles. 
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 Results and Discussion 
None of the tested suspensions with 0.5, 1 or 2 % Na CMC showed sedimentation effects during 
the handling procedure within the study and could be loaded into 2-ml syringes and into the 
injection revolver. Suspensions of methylene blue-loaded microparticles showed a light blue 
color approximately 10 min after preparation (Figure 6-1 B), indicating a surface burst release 
of the dye into the surrounding medium. Suspensions of crystal violet showed a minor 
coloration and were therefore used for the determination of the particle behavior within the 
tissue (C).  
   
 
  
Figure 6-1: SEM image of methylene blue-loaded microparticles (A). Suspension of methylene blue-
loaded lipid microparticles prior to application via a syringe (B); crystal violet-loaded lipid particles 
prior to application (C) distribution of methylene blue along the muscle fibers in the lateral neck muscles 
after injection and longitudinal and horizontal incision (D); crystal violet-loaded-lipid microparticles 
after injection in the lateral neck muscles (E) and after injection in the caudal thigh muscles (F) 
  
A 
A B C 
D E F 
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Both suspensions of methylene blue- and crystal violet-loaded microparticles were easily 
syringeable via 16 and 18 G needles, as well as via the injection revolver into the lateral neck 
muscle. Figure 6-1 D shows the distribution of the dye along the muscle fibers, indicating a 
rapid diffusion of hydrophilic dye into the surrounding tissues although using a carcass. The 
diffusion might even be enhanced when additional movement and body temperature are given. 
Particle residues were not carried away from the injection site and remained in place (Figure 
6-1 E, F). Generally, lesions at injection sites are reported in literature for different kinds of 
food producing animals, which can affect the meat quality concerning tenderness and texture 
[16]. Moreover, it is a fact that a more severe damage in food producing animals is caused by 
the injection of suspensions compared to the injection of solutions [10] [12]. 
 
  
Figure 6-2: Ultrasonographic examination of the lateral neck muscles (A), the caudal thigh muscles 
directly after injection (B) and 1 h after injection (C) 
Additionally, both injection sites, lateral neck and caudal thigh muscles, were characterized via 
ultrasonography (Figure 6-2 A-C). The pig skin and underlying fat layers demonstrate several 
peculiarities in contrast to other mammalian skin. The fat layer consists of five sublayers with 
different thicknesses and fatty acid compositions [17] [18]. Since it was not possible to visualize 
the placement of microparticles after injection into the lateral neck muscles, as they are covered 
by a thicker fat layer, the caudal thigh muscles seemed to be a more suitable site for injection 
and monitoring by ultrasonography. Ultrasound images showed faint shadows along the muscle 
fibers indicating the reconstitution medium, underlining the results obtained by incision [19]. 
Immediately after injection, the liquid reconstitution medium was clearly noticeable (Figure 
6-2 B), but almost faded away after one hour (Figure 6-2 C). Nevertheless, the tested 
microparticles remained in the muscle tissue. The formation of a temporary depot in the tissue 
C
 
B A 
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due to enhanced viscosity of the reconstitution medium, as visible after injection of oily 
suspensions or in-situ forming implants [20], was not observable in both injection sites. For 
oily suspensions, the depot-effect is dependent on the solubility of the drug in the medium and 
the surrounding tissue [21].  
 Conclusion 
The ex vivo pre-testing studies gave us first insights into the behavior of lipid microparticles 
after injection into the two major injection sites in swine. Furthermore, it was possible to 
evaluate the injection via a single-dose injection with a syringe, or a multiple-dose device, the 
commonly used injection revolver. In both cases, the injection could be easily performed.  
The tested hydrophilic dye was partly dissolved out of the lipid particles upon reconstitution 
and could be found along the muscle fibers, whereas the lipid particles remained on the injection 
site. These findings could be confirmed by investigations using ultrasounds, whereby a 
visualization of the microparticles was not possible. The reconstitution medium consisting of 
Na CMC in concentrations of 0.5, 1.0, 2.0 % (m/V) and PS 20 0.02 % (m/V) seemed to be a 
good candidate for further development and optimization, with respect to pH and isotonicity 
for a following use in the in vivo study. In addition, it would be beneficious to keep the amount 
of injected microparticles in a low range to avoid tissue lesions leading to minor meat quality. 
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 IN VIVO EVALUATION OF G [6-D-PHE]-LOADED SOLID LIPID 
MICROPARTICLES WITH SPECIAL REGARD ON ESTRUS 
CONTROL 
 
 
 
 
 
 
 
 
 
Parts of this chapter are intended for publication 
 
 
Data and results in this chapter were gained in cooperation with Prof. Dr. Johannes Kauffold 
and the Faculty of Veterinary Medicine of the University of Leipzig. Investigations on swine 
were performed by Catherine Poser and Rosa Stark, PhD students of Prof. Dr. J. Kauffold with 
the help of Dr. Haukur Lindberg Sigmarsson and Dr. Matthias Hoops. Analysis of the obtained 
data with corresponding statistics was performed by me at the LMU in Munich.  
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 Abstract 
For evaluation of an ecologically compatible alternative intended for cycle blockage and estrus 
control, G [6-D-Phe]-loaded lipid microparticles were tested in vivo. Two different 
reconstitution media were applied to investigate applicability and syringeablilty of the 
suspension, revealing suspension properties for a PVP containing medium. In general, lipid-
based microparticles were well tolerated throughout the studies with only mild reactions on 
injection sites. To evaluate the appropriate dose, 750 µg per animal and 3750 µg per animal 
were administered via different formulations. The low peptide concentration was sufficient for 
a reliable cycle blockage in swine. It was possible to achieve a cycle blockage between 
6.4 ± 0.2 d with D114 + 5 % Span 40 and 14.2 ± 4.9 d with D118 + 10 % GMS. Onset of 
follicular growth could be controlled between 7 and 17 d depending on the formulation, with 
significantly delayed onset of follicular growth in the group treated with D114 + 5 % Span 40 
microparticles. Ovulation was significantly reduced using the high dose formulations compared 
to placebo. The incidence of temporary and permanent ovarian cysts was higher in the treatment 
groups compared to the controls, without statistical evidence. Thus, it could be demonstrated 
that G [6-D-Phe] loaded lipid microparticles are a promising environmentally sustainable 
alternative for cycle blockage and estrus control in swine. 
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 Introduction 
For economic reasons in livestock breeding, animals are estrus synchronized to allow a fixed-
time insemination at a predictable time point [1]–[4]. A variety of gestagens is currently used 
to achieve a cycle blockage [5]–[7]. Allyl trenbolone, also referred to as altrenogest, was one 
of the first synthetic progestogens daily administered to influence the estrus in gilts. A highly 
reliable estrus control can be achieved when fed in doses between 10 and 20 mg/d per animal 
over 14 to 19 days [8]–[11]. Further investigations indicate, that a treatment with altrenogest 
positively influences fertility and litter size of treated animals [12]. 
Besides the use in livestock breeding, gestagens like levonorgestrel and drospirenone are also 
active ingredients of hormonal contraceptives for women [13] [14]. Concerns about the 
intensive use of gestagens arise from their entry into the environment harming fish reproduction 
which results in infertility and masculinization [15]–[17]. Carlsson and co-workers tested a 
variety of drugs towards their effect on the water environment and identified the gestagen 
norethisterone as a substance with high toxicity for water organisms with possible long-term 
effects [18]. The problem is more pronounced due to the absent or if only minimal 
metabolization [16] [19] [20]. Therefore, there is a need for alternatives in the food-producing 
animal industry, where large amounts of gestagens are fed daily and which can enter the 
surrounding runoff, ground and water [19] [21]–[23] 
To achieve estrus control with minimal effects on the environment, the application of GnRH 
analogues, like G [6-D-Phe] is of high interest. The original GnRH decapeptide 
pGlu1-His2-Trp3-Ser4-Tyr5-Gly6-Leu7-Arg8-Pro9-Gly10-NH2 and G [6-D-Phe] are completely 
metabolized to non-toxic components [24]–[26]. The introduction of bulky and hydrophobic 
amino acids in position 6 of the peptide backbone is an important structural change to reduce 
degradation and increase bioactivity [25] [27] [28]. G [6-D-Phe] with D-Phe in position 6 
instead of Gly is a so called superagonist for GnRH I, which has a 2.5-fold longer half-life 
compared to GnRH and shows higher resistance to degradation, due to modification in the 
cleavage point for endogenous peptidases [26] [27] [29]. 
A drawback of G [6-D-Phe] against gestagens in estrus synchronization is the need for 
parenteral application. Since daily injection is not desirable in food animal health, a sustained 
release system appears mandatory. Different delivery systems for GnRH analogues have been 
reported in literature for a diversity of mammalian species [30] [31]. Wenzel et al. incorporated 
GnRH in a sustained release poloxamer gel to achieve a sustained release after depot injection 
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in cattle and to protect the drug against degradation [32]. Further approaches with a successful 
achievement of synchronized estrus was reported in beagle bitches with the incorporation of 
leuprolide acetate into PLGA microparticles followed by treatment with fertirelin [33]. 
Furthermore, a long-term suppression of sexual functions in male and female dogs can be 
achieved with Suprelorin® (Virbac), a deslorelin containing implant based on hydrogenated 
palm oil and Phosphatidylcholine. Similarly, the sexual functions in the macaque could be 
controlled for 3 to 5 months with the delivery of buserelin via an implant [30] [31] [34]–[36]. 
These approaches and promising results from previously performed in vitro studies on 
G [6-D-Phe] loaded microparticles pathed the way for in vivo testing of these systems in swine. 
Effects on cycle blockage, ovulatory behavior, side effects and biocompatibility were to be 
evaluated [37]. Based on a previous study on continuous application of G [6-D-Phe] via pumps, 
consequently 750 µg or 3750 µg per animal were tested [38]. 
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 Materials and Methods 
 Materials 
Gonadorelin [6-D-Phe] (G [6-D-Phe]) was donated by Veyx Pharma GmbH (Schwarzenborn, 
Germany). Triglycerides Dynasan 114 (trimyristin, D114), Dynasan 116 (tripalmitin, D116) 
and Dynasan 118 (tristearin, D118) were kindly provided from Cremer Oleo (Witten, 
Germany). Glycerol monostearate (GMS) with a monoester content of 40-55 % was purchased 
from Caelo (Caesar & Loretz, Hilden, Germany). Sorbitan monopalmitate (Span 40) was 
purchased from Croda (Nettetal, Germany). Mannitol and centrifuge tubes were purchased from 
VWR International GmbH (Darmstadt, Germany). Distilled water produced with a distillation 
apparatus (Wagner und Munz, München, Germany) was used for preparation of reconstitution 
media. Highly purified water was produced using a Milli-Q Water system, (Millipore, MA, 
USA). The gelling agent Tylopur® C 300 (sodium carboxymethylcellulose, Na CMC) was 
kindly donated from Clariant (Muttenz, Switzerland) and Kollidon® 90F (Polyvinyl 
pyrrolidone, PVP) was acquired from BASF (Ludwigshafen, Germany). Polysorbate 20 (PS 20) 
and polysorbate 80 (PS 80) were purchased from Merck KGaA (Darmstadt, Germany). 
 Animals 
German Landrace x Piétrain gilts with a mean weight of 143.8 kg and an average age of 211 d 
at the beginning of the study were used. The animals were weaned from the mother after 28 d 
and kept at a flat deck for further 49 d. Afterwards, the animals were housed in a separate stable 
in pens à 2 animals and fed dependent on the age according to the guidelines of the Deutsche 
Landwirtschaftliche Gesellschaft (DLG) [39]. 
 Preparation of G [6-D-Phe] loaded microparticles by spray congealing 
Lyophilized G [6-D-Phe] was filled in high grade stainless steel beakers and milled using a 
Retsch® Cryomill (Retsch Technology, Haan, Germany) with two stainless steel balls (10 mm 
diameter) applying a precooling time of 10 minutes at 5 Hz followed by the actual milling step 
of 4 minutes at 20 Hz. The obtained powder was aliquoted in 6 R vials, closed with a rubber 
stopper and crimped. Lipid compounds were melted on a hot plate at approximately 90 °C 
(D114, D116) and 110 °C (D118), the aliquot of peptide was added and homogenized using a 
T-10 basic Ultraturrax (IKA Laboratory Technology, Staufen, Germany) for 2 min. The lipid 
dispersion was poured into the sample container of the B-290 Mini spray dryer (Büchi, Flawil, 
Switzerland) with additionally installed spray congealing equipment, which was pre-
conditioned for 1.5 h prior to the production step. The lipid melt was atomized using nitrogen 
at a pressure of 6 bar. A spray flow of 414 l/h was used resulting in a filter pressure of 92 mbar. 
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The aspirator power was set to 100 % throughout all experiments. A dehumidifier Deltatherm® 
LT (Deltatherm® Hirmer GmbH, Much, Germany) was installed keeping the inlet temperature 
at 13-15 °C.  
 Determination of drug content  
20 mg microparticles were weighed into centrifuge tubes, 2.0 ml of methylene chloride and 
2.0 ml of highly purified water were added and the tubes were placed on a horizontal shaking 
incubator GFL 3031 (Gesellschaft für Labortechnik, Burgwedel, Germany) at 39 °C and 60 rpm 
for 12 h. Samples of 1 ml were taken from the water phase and analyzed using RP-HPLC. All 
extractions were performed in triplicate. RP-HPLC analysis was performed using an Agilent 
RP-HPLC system (Agilent, Santa Clara, CA, USA), supplied with a 250 x 4.6 mm Luna C-8 
column(5µm) (Phenomenex, Aschaffenburg, Germany) and a Security Guard™ KJO-482 pre-
column (5 µm) (Phenomenex, Aschaffenburg, Germany). Columns were maintained at 40 °C 
using the following gradient: 
Time [min] A [%] B [%] 
0 65 35 
1 65 35 
21 65 35 
22 10 90 
26 10 90 
35 65 35 
Mobile Phase A: 1000 ml highly purified water + 1 ml trifluoroacetic acid  
Mobile Phase B: 800 g Acetonitrile + 200 g water + 1.2 ml trifluoracetic acid 
 Aliquoting of the particles under laminar air flow 
Based on the drug content (see 7.3.4) microparticles delivering 750 µg or 3750 µg per animal 
for the treatment of six animals were weighed under laminar air flow (LAF) into sterile 10 R 
vials, closed with rubber stoppers and crimped.  
 Preparation of the reconstitution medium 
For the pre-clinical studies, two different reconstitution media were used. Firstly, the 
reconstitution medium consisted of 1 % Na CMC and 0.02 % PS 20. The solution was filtrated 
through a 5 µm-syringe filter into sterilized 10 R glass vials under LAF closed with sterile 
rubber stoppers and sterilized in a table autoclave GTA 50 (Medizin und Labortechnik Fritz 
Gössner, Hamburg, Germany). Optimized reconstitution medium was prepared under LAF 
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conditions using the above-mentioned apparatus by adding 0.5 % PS 80, mannitol for 
isotonization and 3 % Kollidon® 90 F to distilled water while stirring followed by a sterile 
filtration through a 0.22 µm syringe filter. Each vial contained 20 ml of reconstitution medium 
and was closed with sterilized rubber stoppers and crimped. The vials were stored in the 
refrigerator until application. 
 Viscosity measurements 
Both reconstitution media were analyzed on a rotation viscometer MCR 100 rheometer 
(Physica, Anton Paar, Ostfildern, Germany) applying the cone-plate-method at 25 °C. Shear 
rates between 1 s-1 and 100 s-1 were applied. Both pure reconstitution medium as well as particle 
suspension was tested. 100 mg of particles were suspended in 4.0 ml of reconstitution medium. 
Each measurement was performed in triplicate. 
 General study set-up and pre-treatment of the animals 
Both in vivo studies were conducted at the Versuchsgut Oberholz of the University of Leipzig 
between September 2014 and August 2015. Gilts specifically bred for this purpose at age of 
180 days were brought in contact with a boar to detect possible estruses. The study started with 
the ultrasound examination to assure onset of puberty in all participating animals. If this was 
not the case, puberty was induced using Intergonan® 240 IE/ml (equine chorionic gonadotropin, 
eCG, Intervet, Unterschleißheim, Germany). This treatment was only necessary for six animals 
out of 25 in the first study. These animals were again examined for detection of puberty status 
8 d later [39]. 
Prior to application, all gilts were estrus-synchronized to assure that every animal reached day 
12 of the sexual cycle with the 46 day of the study. For cycle synchronization 20 mg/animal 
Regumate® (altrenogest, Intervet, Unterschleißheim, Germany) were applied starting on day 11 
for 28 d. 40 h after the last altrenogest application, 1.000 IE Intergonan® were injected i.m. to 
induce follicular growth. Ovulation was induced by intramuscular injection of 50 µg/ml 
Gonavet® Veyx (G [6-D-Phe], Veyx Pharma GmbH, Schwarzenborn, Germany). With day 46 
of the study, gilts were randomized into five groups, consisting of four treatment groups and 
one control group. The injection of the different formulations started on the same day. Table 
7-1 gives an overview on formulations tested in the first and second pre-clinical study. 
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Table 7-1: Overview of applied treatments and G [6-D-Phe] concentrations per group. Groups 1-5 were 
investigated during the first pre-clinical study in September 2014, groups 6-10 were investigated in 
August 2015 in the second study 
Pre-clinical study 1 Triglyceride Additive/concentration G [6-D-Phe] 
concentration 
[µg/animal] 
1 D118 - 0 (Placebo) 
2 D116 GMS/10 % 750 
3 D118 GMS/10 % 750 
4 D116 GMS/10 % 3750 
5 D118 GMS/10 % 3750 
Pre-clinical study 2 Triglyceride Additive/concentration G [6-D-Phe] 
concentration 
[µg/animal] 
6 D114 Span 40/5 % 0 (Placebo) 
7 D116 Span 40/5 % 750 
8 D114 GMS/5 % 750 
9 D114 Span 40/5 % 750 
10 D114 Span 40/10 % 750 
From day 34 on, the gilts were examined clinically and sonographically with focus on cycle 
state. Moreover, an additional detection of possible estruses was performed with the presence 
of a boar. Injection of microparticle formulations was performed on day 46 followed by daily 
visible inspection of injection sites. All animals were investigated at least 25 days and 
maximum 31 days after injection of the formulations to detect the end of cycle blockage and 
following follicular growth and ovulation [39]. 
 Reconstitution and application of the suspension 
Microparticles and reconstitution medium were delivered in two separate vials and mixed prior 
to application. In general, 50 to 100 mg microparticles (depending on the actual drug load) were 
mixed with 2.0 ml of corresponding reconstitution medium. Each vial contained single doses 
for potentially six animals. The vials were gently shaken for homogenization avoiding foam 
formation. Previous experiments suggested a manual shaking for 2 min, whereas the practical 
application needed reconstitution times of 15 min until homogeneity was reached with the high 
dose formulations. The multi-dose containers were assembled with the injection revolver and 
the respective amount of suspension was injected into the lateral neck muscles. High dose 
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formulations (3750 µg/animal) were suspended in 4 ml of reconstitution medium and 2 x 2 ml 
were injected [39].  
 General examination and evaluation of injection sites 
Gilts were investigated concerning interior body temperature with the means of rectal 
temperature measurement, food intake, general condition and clinical signs of disease between 
days 34 to 72/78. Injection sites were evaluated with special focus on redness, pain, swelling 
and temperature. Results were documented photographically [39]. 
 Determination of estrus control 
Besides contact with a boar, estrus was detected via redness and swelling of the genitals, as 
well as beginning and end of “standing” according to a pre-defined schedule. “Standing” was 
detected via established tests, e.g. back-pressure test by instructed personnel. This data was 
gained as additional information to assure a gilt´s estrus [39]. 
 Ultrasound examination of ovaries  
Ultrasound examinations were performed using a Fazone CB device (Fujifilm, Tokyo, Japan) 
equipped with a convex transducer type C 9-3, achieving a frequency of 3-9 MHz. For our 
investigations, a frequency of 6 MHz was used, which assured a penetration depth of 10 cm. 
Overall gain was set at 84 dB. For examination, the animals were brought into a custom-made 
box and immobilized by feeding. Ultrasound was performed transcutaneously according to 
Kauffold et al., by positioning the transducer from the right ventro-lateral abdominal wall in 
dorsal direction to the last pair of teats and cranial to the hind leg [40]. Structures like follicles, 
corpora haemorrhagica and corpora lutea were monitored and documented. The term ovarial 
cysts was used for structures consisting of growing follicles with a diameter larger than 10 mm 
showing no ovulation. These structures were persistent besides ovulating follicles (solitary 
cysts) or exclusively, then called polycystic ovary degeneration (POD). If they were persistent 
solely over a defined period without influencing the cycle blockage, they were called temporary 
cysts. If monitored over the whole-time period, they were called permanent cysts. Ovulation 
was set as complete, if pre-ovulatory follicles vanished and just corpora haemorrhagica were 
present. Each measurement consisted of at least three representative follicles and if present, 
three corpora lutea to depict the onset of new follicle growth [41]. This value consisted of the 
mean value out of three single measurements for each day, respectively [39]. 
 Statistical Analysis 
Statistical Analysis was carried out using SigmaPlot (Systat Software Inc., San Jose, CA, USA). 
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 Results and Discussion 
 Characterization of reconstitution behavior 
Viscosity measurements were conducted to evaluate applicability of the particle suspensions 
(Table 7-2). 
Table 7-2: Viscosities of reconstitution media and final suspensions 
Formulation Viscosity [Pas] Shear rate [s-1] 
Na CMC 1 % medium 0.041 (± 0.002) 1 
Na CMC 1 % suspension 20.9 (± 13.1) 1 
Na CMC 1 % medium 0.036 (± 0.002) 100 
Na CMC 1 % suspension 0.050 (± 0.006) 100 
PVP 3 % medium 0.014 (± 0.007) 1 
PVP 3 % suspension 8.0 (± 4.2) 1 
PVP 3 % medium 0.007 (± 0.004) 100 
PVP 3 % suspension 0.012 (± 0.002) 100 
In literature, shear thinning and dilatancy are reported for suspensions, depending on medium 
and concentration of the dispersed phase [42] [43]. Both reconstitution media and suspensions 
showed shear thinning behavior. Shear thinning was more pronounced when Na CMC was used 
as thickening agent compared to PVP, possibly due to linear orientation of the colloids like 
cellulose upon mechanical stress [44]. Na CMC based reconstitution medium showed a higher 
viscosity without particles at low shear rates (0.041 ± 0.002 Pas), as well as after suspension 
(20.9 ± 13.1 Pas) compared to the PVP based medium (0.014 ± 0.005 Pas without particles, 
8.0 ± 4.2 Pas with particles). With suspension of particles, both media showed a remarkably 
reduced viscosity after exposure to shear stress in comparison to the unsheared sample 
indicating an orientation of the particles upon shearing. Foam formation was only noticeable 
upon shaking the Na CMC based formulation with the potential of particle loss at the surface 
and inhomogeneity (Figure 7-1). Thus, the reconstitution medium based on PVP appeared to 
be more suitable for reconstitution of the particles, especially with a suspension start viscosity 
of 8 Pas, and a marked shear thinning to 0.012 Pas, which should enable easy syringeability 
and injectability. 
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 Applicability of the final suspensions in vivo 
For both studies two different compositions of reconstitution media were evaluated.  
   
Figure 7-1: Particles suspended in reconstitution medium (Na CMC 1 %, PS 20 0.02 %) with formation 
of foam due to manual shaking and absorption of particles to the surface (A) kindly provided from the 
Faculty of Veterinary Medicine, University of Leipzig. Placebo formulation (D114 + 5 % Span 40) 
during homogenization in reconstitution medium (PVP 3 %, PS 80 0.5 %, mannitol 5 %) (B). 
Homogenous suspension of particles in PVP-based reconstitution medium (C) 
Na CMC-based medium did not show satisfying reconstitution properties specifically for the 
high dose formulations (3750 µg/animal). Particles showed a marked tendency towards 
agglomeration (Figure 7-1 A). To achieve a homogenous suspension, the vials needed to be 
shaken manually for 15 to 30 min, which is not practicable for a market product. Furthermore, 
the formation of foam made it difficult to withdraw the desired volume, which necessitated 
improvement for the second pre-clinical study. Formation of foam could be reduced by 
exchanging Na CMC with PVP, as well as PS 20 by PS 80 and despite increasing the 
concentration of emulsifier from 0.02 to 0.5 %. All verum formulations of the second pre-
clinical study could be suspended and injected. The placebo formulation still required longer 
reconstitution times (Figure 7-2).  
C 
A B C 
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Figure 7-2: Particle suspension in optimized reconstitution medium (PVP 3 %, PS 80 0.5 %, mannitol 
5 %) prior to the application in the injection revolver (A). Injection of the suspension into the pig´s 
lateral neck muscle (B). Marking of the injection site for further examination and documentation of 
adverse reactions (C) 
 Biocompatibility and documentation of adverse drug reactions 
   
Figure 7-3: Adverse reactions documentated in first (A) and second pre-clinical study (B). All values 
are calculated as percentage of the treated animals (control: 5, black bars; treatment 20 animals, grey 
bars). Statistics were performed using a Mann-Whitney-Rank-Sum-test  
The lipid microparticles were well tolerated, which went in accordance with observations from 
other researchers [45]–[47]. None of the gilts showed pain at the injection site in both control 
and treated groups. Throughout the first study, both control and treatment groups did not show 
signs of illness or fever. In the second study one gilt showed fever symptoms directly after 
injection and another after 24 d. Redness of the injection site could be detected in both studies, 
without significant difference between control and treatment groups, possibly reasoned by rapid 
injection without fixation of the animals. In both pre-clinical trials, more animals of the control 
groups showed redness at the injection sites. A significant difference (P-value: 0.04) was 
observed concerning warmth of injection sites in the second study, where a higher percentage 
of the control group showed increased temperature, potentially due to reconstitution problems. 
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Mild swelling was observed in all animals in both control and treatment groups during the first 
study, which could be minimized to 60 % due to better reconstitution properties. Two animals 
showed an intermediate swelling persisting for 4 d (treatment) and for 13 d (control). 
Isotonization with 5 % mannitol and replacement of Na CMC with PVP might be reasons for 
the better compatibility. In general, the treatment with G [6-D-Phe] did not show a significant 
increase in occurrence of adverse reactions compared to control. 
 Effects on cycle blockage in vivo using different formulations and G [6-D-Phe] 
concentrations 
The sustained release G [6-D-Phe]-microparticles were evaluated with respect to minimal 
effective concentration as well as effect on cycle blockage and estrus control. Both placebo 
formulations of the first (D118) and second pre-clinical study (D114 + 5 % Span 40) did not 
influence the cycle (Figure 7-4).  
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Figure 7-4: Duration of cycle blockage after injection of lipid based microparticle formulations. Results 
of the first pre-clinical study using G [6-D-Phe] 750 µg/animal and 3750 µg/animal in D116/D118 
formulations with 10 % GMS (A) as well as D114/ D116 and G [6-D-Phe] 750 µg/animal with addition 
of GMS and Span 40 tested in the second study (B). Data shown are individual results with mean and 
SEM. Statistical analysis was performed by one-way ANOVA followed by pairwise multiple 
comparisons (Holm-Sidak-method) 
Using the formulation D116 + 10 % GMS 750 µg/animal, a cycle blockage of 10.0 ± 2.6 d 
could be achieved with one animal not responding to the therapy. A longer cycle blockage of 
14.2 ± 4.9 d was observed in animals receiving the longer chain triglyceride D118 + 10 % GMS 
750 µg/animal, with one animal not showing a cycle blockage in the observed time. Increasing 
the therapeutic dose to 3750 µg/animal resulted in a cycle blockage of 9.8 ± 4.3 d with two gilts 
not responding to the therapy when treated with D116 + 10 % GMS. The delivery of 3750 µg/ 
animal G [6-D-Phe] formulated in D118 + 10 % GMS led to a cycle blockage of 15.8 ± 4.2 d 
in all animals. Due to high variation within the groups receiving the drug containing 
microparticles, no significant difference between placebo and treatment was observed. The 
**
* 
* 
*
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treatment with the higher dose of G [6-D-Phe] did not lead to a longer cycle blockage and did 
only in case of D118 + 10 % GMS result in a higher response within the group (5/5). In this 
group, one gilt showed a cycle blockage until the end of the observed time (31 d). In the 
treatment group with 3750 µg/animal (D116 + 10 % GMS) two animals did not show a response 
to drug application. Formulations tested in the first study evidenced, that the achievement of 
cycle blockage with the means of lipid based microparticles is generally possible using the low 
dose concentration, confirming the study with osmotic pumps [38]. Increasing the G [6-D-Phe] 
content did not lead to a significant improvement in therapy success or higher synchronicity. 
The highest synchronicity could be observed in the group of D116 + 10 % GMS 750 µg/animal. 
Furthermore, the delivery of a higher dose seemed to have the consequence of a permanent 
cycle blockage, as it was only observed in one of the high-dose groups.  
For the second pre-clinical study, four different formulations were tested delivering 
750 µg/animal of G [6-D-Phe]. The use of D116 + 5 % Span 40 resulted in a cycle blockage of 
4.6 ± 1.5 d, with all animals responding to the therapy but a high variability within responses. 
The effect of cycle blockage was significantly different compared to placebo (P-value: 0.017). 
The group treated with D114 + 5 % GMS showed a cycle blockage of 2.8 ± 1.4 d with one 
animal not showing a cycle blockage. Formulation consisting of D114 + 10 % Span 40 led to a 
cycle blockage of 1 day ± 0.5 days with two animals not responding to the therapy. Best results 
throughout all studies could be achieved with the formulation D114 + 5 % Span 40, where all 
treated gilts showed a cycle blockage and the highest synchronicity could be observed (5/5). 
Hence, a cycle blockage of 6.4 ± 0.2 d was achieved with a significant difference to the control 
group (P-value < 0.001) and to the group treated with the formulation D114 + 10 % Span 40 
(P-value: 0.005). Consequently, duration of cycle blockage was closest to the desired cycle 
blockage of 15 days using D116 + 10 % GMS 750 µg/animal, whereas highest synchronicity 
was observed when D114 + 5 % Span 40 was used. These findings confirmed that it was 
possible to achieve a cycle blockage with the use of a sustained release G [6-D-Phe] 
formulation. 
 Influence on follicular growth  
Onset of follicular growth is another parameter indicating success of the therapy. The follicular 
growth started after 7 to 7.5 d in both control groups, which represented the regular duration 
time between diminishment of altrenogest and onset of follicular growth. After treatment with 
D116 + 10 % GMS 750 µg/animal, follicles started to grow after 14.4 ± 2.8 d. Exchanging the 
triglyceride to D118 + 10 % GMS 750 µg/animal led to an onset of follicular growth after 
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14.8 ± 3.1 d, leading to a permanent cycle blockage in one treated animal. An increase in 
G [6-D-Phe] dose to 3750 µg/animal resulted in onset of follicular growth after 14.2 ± 4.1 d 
(D116 + 10 % GMS) and 17 ± 2.0 d (D118 + 10 % GMS), where one animal did not show 
follicles after the monitored time. Due to considerably high variability within the groups, no 
significant difference between treatment and control groups could be detected, although 
follicular growth was delayed.  
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Figure 7-5: Onset of follicular growth after treatment with lipid microparticle formulations. (A) Results 
of the first pre-clinical study using of G [6-D-Phe] 750 µg/animal and 3750 µg/animal) in D116/D118 
formulations with 10 % GMS. (B) Results of follow-up study using D114/D116 with addition of GMS 
and Span 40 and 750 µg/animal G [6-D-Phe]. Data shown are individual results with mean and SEM. 
Statistical analysis was performed by Kruskal-Wallis-one-way ANOVA on ranks (A) and by one-way-
ANOVA followed by pairwise multiple comparisons (Tukey-test) (B). * one animal with persistent 
cycle blockage observed 
In the second study, treatment with D116 + 5 % Span 40 resulted in an onset of follicular 
growth after 11.6 ± 1.5 d. After the treatment with D114 + 5 % GMS follicles occurred after 
9 ± 1.9 d. Most promising results were achieved with the use of D114 + 5 % Span 40 particles, 
where an onset after 13.4 ± 0.2 d was monitored. This difference compared to the control group 
was significant (P-value < 0.05). Increasing the concentration of Span 40 to 10 % shortened the 
interval between discontinuation and onset to 7.8 ± 0.6 d. Growing follicles were visible in all 
treated animals in this study. Thus, the formulation D114 + 5 % Span 40 showed in cycle 
blockage, synchronicity and onset of follicular growth the most promising results. 
 Influence of treatment on ovulatory behavior 
Another important parameter for a successful reproduction is the occurrence of ovulation of 
growing follicles. Treatment with altrenogest is known to improve ovulation rates and 
following litter sizes compared to controls [10]. GnRH and its analogues are indicated in 
ovulation induction in human and veterinary medicine [48]–[50]. Therapy-associated ovulation 
within all groups was compared in order to investigate, if the treatment affected ovulation 
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behavior in gilts. Both control groups, D118 and D114 + 5 % Span 40 resulted in a 100 %-
ovulation observation within the ten tested animals. In the group treated with D116 + 10 % 
GMS 750 µg/animal only 60 % of treated gilts showed an ovulation. This value was reduced to 
40 %, when the formulation D118 + 10 % GMS 750 µg/animal was used instead. A complete 
anovulatory behavior was observed in the treatment group consisting of D116 + 10 % GMS 
3750 µg/animal where none of the treated gilts showed ovulatory behavior. Here, a significant 
difference compared to the placebo group was monitored (P-value < 0.008). Since the other 
high dose group did also show a decreased ovulation behavior with statistical significance 
(20 % of the gilts in this group ovulated, P-value 0.043), the application of the high G [6-D-Phe] 
dose could be regarded as responsible for this effect. 
 
Figure 7-6: Observed ovulation percentage after treatment with lipid-based microparticles in the first 
study. Each bar represents the percentage out of 5 animals per group. Statistical analysis was performed 
using the one-way ANOVA test followed by a Holm-Sidak pairwise comparison.  
In the second study, treatment with D116 + 5 % Span 40 and D114 + 5 % GMS resulted in 
reduced ovulation percentage to 20 %. The formulation with best performance concerning cycle 
blockage and follicular growth, D114 + 5 % Span 40, led to an ovulation in 40 % of treated 
animals. The highest percentage regarding ovulation was observed with the use of 
D114 + 10 % Span 40 (80 %). In the second study, no statistical evidence of reduced ovulation 
compared to control was given. Nevertheless, a higher incidence of anovulatory behavior was 
observed upon treatment with sustained release G [6-D-Phe], whereas only the high dose 
treatment led to significantly reduced occurrence of ovulation. The possible connection 
between sustained release treatment with a GnRH-analogue and absence of ovulation and 
development of ovarian cysts needs to be clarified due to a possible disruption in down-
regulation mechanism [51] [52].  
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Figure 7-7: Observed ovulation percentage after treatment with lipid-based microparticles in the second 
pre-clinical study. Each bar represents the percentage out of 5 animals per group. Statistical analysis 
was performed using the Kruskal-Wallis one-way ANOVA on ranks followed by a pairwise multiple 
comparison (Tukey-test) 
 Evaluation of the relation between treatment and the occurrence of temporary and 
permanent cysts 
The occurrence of ovarian cysts is a critical point in estrus synchronization, as it has negative 
influence on performance of ovaries and success of insemination. Although GnRH analogues 
are used for the treatment of ovarian cysts [53] [54], therapy-induced formation of abnormal 
follicular structures is reported in literature in both human and veterinary medicine [51] [55] 
[56]. Polycystic ovarian degeneration (POD) is characterized by the occurrence of numerous 
liquid-filled cysts accompanied by an absence of c. lutea [40]. A higher incidence of POD was 
observed in estrus synchronization when lower doses (16 mg) of altrenogest were compared to 
higher doses (20 mg) [4]. Consequently, the parameter cyst formation was included in 
evaluation of treatment with a sustained release G [6-D-Phe] delivery system. In both control 
groups, none of the gilts showed permanent or temporary cysts (Figure 7-8). In contrast, 
treatment with D116/D118 + 10 % GMS 750 µg/animal led to the development of permanent 
cysts in 40 % of treated gilts (Figure 7-8 A black bars). Increasing the dose to 3750 µg/animal 
resulted in the development of permanent and temporary cysts in 20 % of treated gilts when 
treated with the formulation D118 + 10 % GMS 3750 µg/animal.  
The formulation D118 + 10 % GMS 3750 µg/animal did not lead to the occurrence of cysts at 
all. During the second pre-clinical study, three treatment groups (D116 + 5 % Span 40, 
D114 + 5 % GMS, D114 + 5 % Span 40) showed an occurrence of permanent cysts in 40 % of 
the animals per group. A lower value of 20 % resulted with the formulation D114 + 10 % Span 
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40. Only the treatment with D116 + 5 % Span 40 microparticles resulted in the development of 
temporary cysts in 20 % of the animals. 
 
  
Figure 7-8: Percentage of observed cysts (permanent: black bars, temporary: grey bars) during the 
treatment with G [6-D-Phe]-loaded lipid based microparticles monitored in the first pre-clinical study 
(A) and the follow-up study (B). Each bar represents the percentage out of the population of 5 animals 
per group. Statistical analysis was performed using the Kruskal-Wallis one-way ANOVA test on ranks 
Kauffold et al. reported a very low incidence of the severe POD in gilts compared to sows upon 
estrus synchronization with gestagens and gonadotropins [40]. Besides the occurrence of single 
temporary or permanent cysts in our experiments, the severe POD did not occur. Although there 
was no statistical evidence, treatment with sustained release G [6-D-Phe] and the occurrence of 
cysts should be evaluated in a larger group of treated animals. The occurrence of follicular cysts 
is reported to be a severe disorder followed by infertility [40]. In literature, the treatment with 
LHRH-analogues is indicated in the presence of ovarian cysts in dairy cows  also in 
combination with cloprostenol to treat these abnormal follicles [53] [57]. A possible 
explanation for this contradictory effect might be, that a treatment with gonadotropins possibly 
changes LH:FSH ratio, necessary for normal follicles as stated by Breen and Knox [58]. Also 
in human medicine, an increased development of follicular and luteal cysts was reported as 
complication during preparation for in vitro fertilization by the application of GnRH-analogues 
[55] [56] [59]. 
 Conclusion 
Our results showed that it was possible to achieve a cycle blockage with a sustained release 
formulation of G [6-D-Phe] in swine. Spray congealed solid lipid microparticles are a suitable 
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delivery system to influence and control the estrus. Particles were prepared without using 
organic solvents and were evaluated to be well tolerated and highly biocompatible in both in 
vivo studies.  
Reconstitution and application of the microparticular suspension was difficult with the use of a 
Na CMC-based medium. Especially when high particle doses (3750 µg/animal) needed to be 
administered, foam formation and attachment of particles to the liquid/air interface occurred. 
These drawbacks could be avoided using the optimized, PVP-based medium with higher 
emulsifier concentration, facilitating reconstitution and application. 
The first study confirmed the successful estrus control with the use of 750 µg/animal 
G [6-D-Phe] resulting in a mean cycle blockage of 10 to 16 d with an onset of follicular growth 
after 15 to 17 d. These values came very close to the desired cycle blockage of 15 d. Here, a 
treatment with D116 in combination with 10 % GMS resulted in the highest synchronicity 
within the group. Compared to the placebo treatment, a significant reduction in ovulation was 
observed after the application of the higher dose (3750 µg/animal) and without statistical 
evidence after treatment with 750 µg/animal. Three out of four treated groups showed 
development of temporary and permanent follicular cysts without statistic relevance compared 
to controls. 
Having proven our concept with the first pre-clinical study, the second study focused on the 
application of 750 µg/animal via four different formulations to narrow the time window to the 
desired 15 d with a higher synchronicity. Best results were achieved with the formulation 
D114 + 5 % Span 40, where a duration of 6 d and the highest synchronicity in all trials could 
be observed. Follicular growth was setting in between 9 and 13 d after application. No 
significant differences in ovulation behavior between treatment and control was observed. All 
treatment groups showed development of ovarian cysts indicating a correlation between 
treatment with G [6-D-Phe] and the occurrence of these structures, without statistical evidence.  
In summary, it is possible to achieve a cycle blockage in variable time frames with the 
application of G [6-D-Phe]-loaded microparticles by variating the type of emulsifier, as well as 
its concentration. Furthermore, we confirmed, which is economically favorable, the successful 
control of estrus cycle with the low dose G [6-D-Phe]. 
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 Abstract 
The lead candidate from the first clinical study was investigated concerning long-term stability. 
Microparticles were stored at 2-8, 25 and 40 °C and samples were taken after 0, 1, 3, 6, 9 and 
12 months. Analysis of particle size, reconstitution properties, lipid polymorph, peptide content 
and release behavior was performed. Formulations showed particle agglomeration upon 
storage, which was minor at 2-8 °C and most pronounced when stored at 40 °C. Reconstitution 
to a homogenous suspension was possible with samples stored at 2-8 °C and 25 °C but limited 
after 40 °C storage. Drug content was not affected in any sample by storage even after 
12 months at 40 °C and no degradation products were detected. The initially observed release 
over two weeks was preserved when microparticles were stored at 2-8 °C. Storage at higher 
temperatures led to a higher burst and a more complete release. Thermal analysis revealed the 
transformation of the initially obtained α-polymorph to the thermodynamically more stable β-
form after storage at 40 °C. Upon storage at 2-8 °C, the α-modification was maintained over 12 
months, whereas XRPD of samples stored at 25 °C already indicated ongoing transitions. Thus, 
storage at 2-8 °C was highly recommended to assure stability with a reliable release profile 
accompanied by good reconstitution behavior and peptide integrity.  
 Introduction 
Lipid microparticles are a promising tool for the sustained release of peptides and proteins [1]–
[5]. We developed microparticles loaded with G [6-D-Phe] which showed drug release over 
two weeks in vitro as well as efficacy in vivo [6]. Consequently, the stability of these 
microparticles was tested at different temperatures over 12 months. Ideally, the product should 
be stable at ambient temperature to enable easy handling by veterinarians and farmers. It should 
further guarantee a continuous release in a two-week time window. Furthermore, particle size 
and lipid polymorph must be preserved [7] [8]. Another major aspect is the integrity of the 
incorporated peptide. 
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 Materials and Methods 
 Materials 
Gonadorelin [6-D-Phe] (G [6-D-Phe]) was donated by Veyx Pharma GmbH (Schwarzenborn, 
Germany). The triglyceride Dynasan 118 (tristearin, D118) was kindly provided from Cremer 
Oleo (Witten, Germany). Glycerol monostearate (GMS) with a monoester content of 40-55 % 
was purchased from Caelo (Caesar & Loretz, Hilden Germany). Ultrapure deionized water with 
a conductivity of less than 0.055 µS/cm (Milli-Q Water systems, Millipore, MA, USA) was 
used for preparation of buffers and mobile phases in this study. Visking dialysis tubings with a 
diameter of 1.6 mm and a cut-off of 12-14 kDa for performance of release studies were sourced 
from Serva Electrophoresis GmbH (Heidelberg, Germany). Centrifuge tubes were purchased from 
VWR International GmbH (Darmstadt, Germany). The reconstitution medium consisted of 1 % 
Tylopur® C 300 (sodium carboxymethylcellulose, Na CMC, Clariant, Muttenz, Switzerland) and 
0.02 % polysorbate 20 (PS 20, Merck KGaA, Darmstadt, Germany) in distilled water (Wagner und 
Munz, München, Germany). All other chemicals were of analytical grade. 
 Production of Gonadorelin [6-D-Phe]-loaded microparticles  
Lyophilized G [6-D-Phe] was milled using a Retsch® Cryomill (Retsch Technology, Haan, 
Germany) using two stainless steel balls (10 mm diameter) with a precooling time of 10 min at 
5 Hz followed by the actual milling step of 4 min at 20 Hz. The obtained powder was aliquoted 
under nitrogen atmosphere. 10.6 g of D118 and 1.2 g of GMS were melted on a hot plate at 
approximately 90 °C. 200 mg of peptide was added and homogenized using a T-10 basic 
Ultraturrax (IKA Laboratory Technology, Staufen, Germany) for 2 min. The lipid dispersion 
was poured into the sample container of a B-290 Mini spray dryer (Büchi, Flawil, Switzerland) 
with additional spray congealing equipment, which was pre-conditioned for 1.5 h (sample 
container 110 °C, inlet temperature 13-15 °C) prior to the production step. The additional 
equipment consisted of a sample container, surrounded by a PEG 400 bath, whereas the sample 
container was connected to the nozzle via a silicon tubing heated with an external resistance 
wire-based heating to approximately 70 °C. The melt was sprayed using nitrogen as spray gas 
at 6 bar spray pressure resulting in a spray flow of 414 l/h and with aspirator power set at 100 %.  
 Storage conditions and study set-up 
For each sampling point, samples of approximately 350 mg were stored at 2-8, 25 and 40 °C in 
two glass vials. Microparticles were weighed under LAF conditions using a HeraSafe HSP 12 
(Heraeus, Hanau, Germany), closed with rubber stoppers and crimped. Analysis was performed 
after 0, 1, 3, 6, 9 and 12 months. 
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 Macroscopic inspection of the microparticles 
Microparticles were visually inspected concerning appearance and aggregation behavior. 
Documentation was performed using a Nikon D5300 (Nikon, Tokyo, Japan) equipped with a 
macro-objective.  
 Observation of surface morphology by scanning electron microscopy (SEM) 
A Jeol JSM 6500-F SEM (Jeol, Tokyo, Japan) was used for SEM images at a voltage of 2 kV 
using a magnification of 150, 900 and 1500 for each sample. Microparticles were fixed on 
aluminum sample holders with black, double adhesive tape (Plano GmbH, Wetzlar, Germany) 
and were analyzed without additional graphite coating.  
 Stability of the suspension 
Approximately 200 mg of stored microparticles were shortly shaken in a glass vial and 2 ml of 
reconstitution medium were added via a syringe through the rubber stopper. The dispersion was 
vigorously shaken by hand for approximately 20 s to suspend the particles in the surrounding 
medium. Photographic images were taken immediately after reconstitution and after standing 
times of 2, 5, and 10 min. 
 Particle size analysis using laser diffraction 
Approximately 20 mg of microparticles were suspended in an aqueous 0.02 % PS 20 solution 
and analyzed using the laser diffraction system Horiba Partica-LA 950 (Horiba, Kyoto, Japan). 
 Determination of polymorphic behavior by differential scanning calorimetry 
(DSC) 
Samples of 5-15 mg microparticles in aluminum crucibles were analyzed using a Mettler DSC 
821e (Mettler Toledo, Columbus, OH, USA) at a heating and cooling rate of 10 K/min from 
0 °C to 110 °C in two cycles against an empty crucible as reference. 
 X-Ray powder diffraction (XRPD) measurements 
A PANalytical Empyrean (PANalytical, Almelo, the Netherlands) equipped with a copper 
anode (45 kV, 40 mA, Kα1 emission, λ = 0.154 nm) and a PIXcel3D detector between 5-50 ° 
2-Theta with a step of 0.039 ° was used for XRPD measurements. 
 Drug content analyzed via RP-HPLC 
Approximately 10 mg microparticles were weighed into centrifuge tubes and dissolved in 
2.0 ml of methylene chloride. 2.0 ml of HPLC gradient grade water (Fisher Chemical, 
Loughborough, UK) were added and the tubes were placed in a Stuart tube rotator SB 3 at a 
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rotation speed of 10 rpm (Bibby Scientific Limited, Stone, UK) at ambient temperature for 
45 min. Samples of 1 ml were taken from the water phase and analyzed using RP-HPLC. Each 
stored microparticle sample was extracted in duplicate. RP-HPLC analysis was performed 
using a Varian RP-HPLC system (Varian Inc., Palo Alto, CA, USA), supplied with a Luna C-
8-column (Phenomenex, Aschaffenburg, Germany) and the guard column SecurityGuard 
(Phenomenex, Aschaffenburg, Germany). Columns were maintained at 40 °C and using the 
following gradient: 
Time [min] A [%] B [%] 
0 65 35 
1 65 35 
21 65 35 
22 10 90 
26 10 90 
35 65 35 
Mobile Phase A: 1000 ml highly purified water + 1 ml trifluoracetic acid  
Mobile Phase B: 800 g Acetonitrile + 200 g water + 1.2 ml trifluoracetic acid 
An injection volume of 20 µl was used for each sample and calibration standards. The actual 
drug content was normalized to a theoretical initial weight of 10.0 mg. This analysis was 
performed by Biopept-Feinchemie GmbH, Weinbergen/Grabe. 
 Determination of release behavior 
50 mg of microparticles were transferred into dialysis tubings, which were previously closed at 
one side with a cotton string. 2.0 ml phosphate-buffered saline (PBS) pH 7.4 preserved with 
0.05 % NaN3 and five glass balls (0.2 mm diameter) for additional weight were added to 
suspend the microparticles. The closed tubings were placed in 50 ml-centrifuge tubes, 
15 ml PBS were added and the samples incubated on a horizontal shaking incubator GFL 3031 
(Gesellschaft für Labortechnik, Burgwedel, Germany) at 39 °C and 60 rpm. At predetermined 
time points, samples of 1 ml volume were taken, replaced by fresh PBS and stored at 2-8 °C 
until HPLC analysis was performed. An Agilent HPLC system (Agilent, Santa Clara, CA, USA) 
was used using the setup mentioned in 8.3.10.   
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 Results and Discussion 
 Influence of storage time and -conditions on particle morphology, -size and 
polymorphic behavior 
G [6-D-Phe]-containing, freshly prepared microparticles appeared as fine powder without 
agglomerates (Figure 8-1). Manual shaking of the vial did not lead to adherence of the particles 
to the chamber wall, which indicated little electrostatic charging, as frequently observed for 
spray dried products [9] [10]. SEM images revealed a smooth and regular surface [11]–[13]. 
The smooth surface obtained after production of lipid microparticles by spray congealing 
frequently comes with the presence of metastable polymorphs [13]–[16]. The α-form with the 
lowest melting point obtains very small crystals and a hexagonal orientation of the carbon 
chains, which enable less chain-chain-interaction and a loose packaging [17]–[19]. The α-
polymorph was confirmed by DSC and XRPD (see 8.4.1). 
0 M  
   
Figure 8-1: Appearance of microparticles directly after production 
After storage time of one month at 2-8 °C, particles still appeared as a fine powder. 
Reconstitution could be performed easily in the reconstitution medium resulting in a stable 
suspension over the monitored time of 10 min. Neither irregularities nor an increased roughness 
were observed on the microsphere´s surface. The 25 °C stored samples showed a tendency 
towards agglomeration (Figure 8-2). Upon shaking, the larger agglomerates could be easily 
separated and reconstitution could be performed without extending the reconstitution time. 
Samples stored at 40 °C formed a sintered cake already after one month. Complete 
disintegration could not be achieved by vigorous shaking after adding the suspension medium. 
The formation of larger agglomerates was also observed in the SEM, where non-spherical, large 
particles with a rougher and more irregular surface were monitored.  
For this reason, analysis after reconstitution was stopped after one month and only polymorph 
and peptide analysis were performed at the later time points. 
The mean particle size of 25 µm at T0 was increased to 50 µm after one month at 2-8 °C, 60 µm 
at 25 °C and 58 µm at 40 °C (Figure 8-4). Samples analyzed at 40 °C were not representative 
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since the large sintered clumps were not removed from the sample prior to analysis. In the 
samples stored at 2-8 °C and 25 °C no increase in particle size can be found in SEM. Thus, the 
increased particle size obtained in laser diffraction can be referred to larger agglomerates. 
1 M 
2-8 °C 
   
25 °C 
   
40 °C 
   
Figure 8-2: Appearance of microparticles after 1 M storage at 2-8, 25 and 40 °C 
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3 M 
2-8 °C 
   
25 °C 
   
40 °C 
   
Figure 8-3: Appearance of microparticles after 3 M storage at 2-8, 25 and 40 °C 
Further storage for three months at 2-8 °C did not affect the shape and morphology of particles 
(Figure 8-3). Particles still showed a smooth surface without irregularities. Particle size was 
similar to the one-month time point. Agglomerates could be seen macroscopically after three 
months at 25 °C which could easily be separated by manual shaking. SEM images revealed the 
formation of larger particle agglomerates. A closer look on the surface showed, that the particles 
exhibited a rougher surface indicating lipid crystallization [13] [18]. This effect was even more 
pronounced in the samples stored at 40 °C with large sintered agglomerates in SEM and flaky 
crystal structures on the surface. This “blooming” and growth of larger flake- or needle-
like structures corresponds to the conversion into the more stable β-polymorph (see Figure 8-7 
and Figure 8-8) [18] [20]. Laser diffraction demonstrated further increase in particle size to 
90 µm after three months at 25 °C (Figure 8-4).  
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Figure 8-4: Mean particle size measurement using laser diffraction over a 12-month storage time at 2-
8, 25 and 40 °C (Mean and SD, n = 3, left); Reconstitution of 2-8 °C-stored samples after 6 months 
exemplarily for acceptable reconstitution properties (right) 
Comparable results were obtained for samples stored for six and nine months. At 2-8 °C 
particles kept their shape without changes in surface morphology, whereas particles stored at 
25 and 40 °C showed a high tendency to agglomeration. Figure 8-4 (right) shows exemplarily 
the suspension of reconstituted microparticles stored at 2-8 °C in the medium, giving evidence 
to good reconstitution properties. At 40 °C, the microparticles had formed a dense cake which 
needed to be crushed prior to SEM analysis and could not be analyzed providing meaningful 
data. Laser diffraction results were comparable to three-month data. 
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6 M 
2-8 °C 
   
25 °C 
   
40 °C 
   
Figure 8-5: Appearance of microparticles after 6 M storage at 2-8, 25 and 40 °C 
After twelve months, no further changes were observed for microparticles stored at 2-8 °C 
(Figure 8-6). Compared to previous time points the results after twelve months did not 
significantly change regarding particle appearance, morphology, size and agglomeration. 
Overall, storage temperature had a major influence on particle agglomeration and surface 
roughness. SEM and particle size measurements indicated crystallization phenomena as well as 
agglomeration in the samples stored at 25 and 40 °C [21]. Samples stored at 2-8 °C only showed 
a slight tendency to formation of agglomerates. 
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12 M 
2-8 °C 
   
25 °C 
   
40 °C 
   
Figure 8-6: Appearance of microparticles after 12 M storage at 2-8, 25 and 40 °C 
Polymorphic behavior of lipids has been discussed as a stability problem [22]–[26]. To 
investigate polymorphic transitions, DSC-thermograms were recorded, which proved the 
presence of the lower melting α-polymorph within the particles directly after production 
(Figure 8-7). A melting endotherm of 55 °C indicates the α-form, whereas the β´- and β-
modification melt at higher temperatures of approx. 63 and 73 °C [27] [28]. The polymorph did 
not change over a twelve-month storage at 2-8 °C. This observation was in good agreement 
with literature that the α-polymorph is stable at low storage temperatures [29]. As 
polymorphism or recrystallization are known to influence release kinetics, a conservation of the 
initially observed polymorph is important [8] [30] [31]. At 25 °C, same effects are visible. Upon 
storage at 40 °C, formation of the higher melting β-polymorph was already completed at least 
after one month. This observed effect corresponds to the transition obtained in Chapter two for 
microparticles and for tempering of triglyceride-based implants to form the stable β-polymorph 
as described by Kreye et al. [8]. Whereas addition of emulsifiers like sorbitan esters may 
stabilize the α-polymorph, others are reported to enhance α-β transition [24] [25] [32]–[34].  
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Figure 8-7: Representative DSC thermograms of microparticles stored at (A) 2-8 °C; (B) 25 °C; (C) 
40 °C (n = 2); sampling was performed after 0, 1, 3, 6, 9 and 12 months 
These findings were confirmed by XRPD measurements of the 12 M sample (Figure 8-8). After 
one year at 2-8 °C microparticles were present in the α-polymorph (one single peak at 21 ° 
characteristic for the α-modification) [19] [35]. Storage at 25 °C resulted in the presence of both 
α- and β-polymorph with a more α-polymorph pronounced pattern [19] [15]. In contrast, the 
sample stored at 40 °C showed the characteristic pattern of the β-modification with three peaks 
at 18, 23 and 25 ° [19]. These observations confirmed the data obtained by DSC measurements 
and underline that a storage at 2-8 °C is mandatory in terms of crystallization of the lipid matrix. 
Overall the storage effects are typical for triglycerides, whereas the presence of additives [23] 
[36] [37] and drug types influence crystallization behavior [18]. Due to rapid cooling during 
the spray congealing process, the crystallization of the triglyceride D118 in the lower melting 
α-polymorph is enabled. Several tempering steps, additionally performed directly after 
production, are reported for implants, to allow an accelerated crystallization to the β-polymorph 
[8] [38]. 
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Figure 8-8: Representative XRPD measurement of the 12 M-stored samples at 2-8, 25 and 40 °C. Single 
graphs were displaced along the ordinate for better visualization (n = 2)  
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 Drug content and release behavior as a function of storage time and temperature 
The drug content in the lipid matrix did not change significantly over one year at 2-8, 25 and 
40 °C (Figure 8-9). Stability was even reported for proteins, like BSA directly after 
encapsulation into lipid microparticles produced by spray congealing [5]. The minor variability 
in drug content was due to the used extraction method based on methylene chloride. 
Furthermore, no degradation peaks were detected in HPLC. Encapsulated G [6-D-Phe] was not 
affected by higher storage temperature and the process itself, as reported for other peptide drugs 
[13]. 
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Figure 8-9: G [6-D-Phe] content in D118 + 10 % GMS microparticles during a 12-month storage time 
at 2-8, 25 and 40 °C (mean and SD, n = 3) 
The most important characteristic for the developed drug delivery system was to guarantee the 
required release profile. Particle size and morphology, as well as an integer matrix with the 
same polymorphic modification have a major influence on release behavior.  
Freshly prepared microparticles showed a burst of approximately 45 % followed by a 
continuous release until day 21 releasing 70 % of incorporated drug. Regarding a storage at 2-
8 °C, the release profile did not significantly change over a one year storage. 
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Figure 8-10: Release profile of G [6-D-Phe] microparticles consisting of D118 + 10 % GMS after a 
storage at 2-8 °C (mean and SD, n = 3) 
Monitoring release behavior after a one year storage at 25 °C, the profile differed considerably 
from the original formulation. Already after one month, the burst was remarkably increased 
without a sustained drug release following. Enhanced release profiles could also be observed 
for triglyceride implants after thermal treatment and applying higher extrusion temperatures [8] 
[31]. 
Higher storage temperatures are reported to massively influence release rates from lipid-based 
microspheres, due to change in microstructure of the lipid matrix [39] as well as the polymorph 
[18]. After one month at 40 °C, the initial burst increased to 80 % without following sustained 
release. Overall, an amount of 95 % was released. The effect became more pronounced over 
one year storage. This change in release profile may be attributed to the polymorph change and 
the sintering of the microparticles corresponding to change in the surface area and the inner 
structure [30] [34] [40]. 
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Figure 8-11: Release profile of G [6-D-Phe]-loaded microparticles consisting of D118 + 10 % GMS 
after a storage at 25 °C (mean and SD, n = 3) 
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Figure 8-12: Release profile of G [6-D-Phe]-loaded microparticles consisting of D118 + 10 % GMS 
after a storage at 40 °C (mean and SD, n = 3) 
Thus, the G-[6-D-Phe]-loaded D118/GMS microparticles need to be stored at 2-8 °C to assure 
the preferred release profile with a continuous in vitro release of two weeks. Peptide stability 
was not impaired by storage at higher temperature. Furthermore, particle agglomeration could 
be minimized at 2-8 °C and the initial polymorphic structure could be kept upon further storage. 
In contrast, storage at 25 and 40 °C did lead to transition to the thermodynamically stable β-
polymorph and particle sintering. 
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 Conclusion 
G [6-D-Phe] in D118/GMS microparticles were stored over one year at 2-8, 25 and 40 °C and 
analyzed for particle morphology, size, agglomeration, lipid polymorph, drug content and 
resulting release behavior. Storage at 2-8 °C was mandatory to ensure minimal particle 
agglomeration and to guarantee the presence of the initially observed α-polymorph. 
Polymorphic transition, accompanied with blooming on the surface occurred upon storage at 
25 and 40 °C: Release behavior could only be maintained at a storage temperature of 2-8 °C. 
Furthermore, reconstitution behavior was not affected upon one year storage at 2-8 °C. The 
study confirmed the stability of G [6-D-Phe] after encapsulation into lipid-based microparticles 
at all storage temperatures without peptide degradation. 
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The main goal of this work was the development of a microparticular, sustained release delivery 
system for the peptide drug gonadorelin [6-D-Phe], which is currently used in combination with 
other substances to influence the reproductive cycle in swine [1] [2]. Our final product should 
provide an environmentally friendly alternative for estrus synchronization in swine. Due to 
harmful effects on fish with detrimental effects on their reproduction, it is necessary to avoid 
the pollution of ground water with higher amounts of gestagens and their active metabolites 
[3]–[6]. Commonly used gestagens are usually fed in amounts of 15-20 mg/d over a time period 
of 10 to 18 days [7]–[9]. The peptide drug G [6-D-Phe] is a promising, rapidly metabolized 
alternative.  
Chapter One reviews the state of the art of polymer-based delivery systems with special focus 
on the delivery of peptides and proteins. Manufacturing techniques, especially for lipid 
microparticles are discussed. Furthermore, different regimen and drugs currently used for estrus 
synchronization in livestock animals are introduced. Due to good physiological tolerance, lack 
of side effects and the low costs, solid lipids were of special interest for the development of a 
sustained release drug delivery system. For the injectable, controlled release system for G [6-
D-Phe] for an intended release over two weeks, microparticles represent the ideal system. 
The spray congealing process was investigated in Chapter Two to establish suitable process 
settings with a focus on yield and particle size. Microparticles could be produced using the 
triglycerides D116, D118 and D120 with a round shape and smooth surface. The placebo 
particles were only marginally influenced by the applied spray flow and product flow, with an 
overall stable process. The achieved particle size was between 30 and 70 µm. The triglyceride 
particles exhibited the low melting α-polymorph, which can be transformed to the β-form upon 
tempering for 24 h at 45 °C. 
Chapter Three dealt with the incorporation of hydrophilic model substances, specifically 
tryptophan and aspartame. A suitable system for the determination of drug release was 
developed. Pure triglycerides did not provide a sustained release profile. Addition of surfactants 
like GMS led to an increased burst release and a more complete drug release of tryptophan. The 
release could be controlled between 8 (5 %) and 24 d (10 % GMS). The addition of lipase to 
the release medium enhanced drug release. For aspartame, the addition of 5 and 10 % Span 40 
was most promising for the release duration, which reached 12 days. 
Since the product yield upon spray congealing was still low, the manufacturing process was to 
be optimized before production of G [6-D-Phe] microparticles in Chapter Four. High material 
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losses occurred in the spray tower and the sample container. Yield could be improved by 
increasing the spray flow, reducing the melt temperature and by installation of a vibrating 
stirrer. The encapsulation efficiency and particle size could be improved by a reduction of the 
spray flow. Additionally, a reduction of melt temperature followed by an increased viscosity 
had a positive effect on encapsulation efficiency. 
The peptide drug G [6-D-Phe] could successfully be incorporated into spray congealed lipid 
microparticles at a theoretical concentration of 1.8 %, which was shown in Chapter Five. A 
broad screening revealed formulations with a high potential for a sustained release over two 
weeks. Most promising release profiles could be obtained by the addition of 5 and 10 % GMS 
and Span 40, with a continuous release up to 22 d. Burst release could be reduced by the 
suspension of lipid microparticles in thermosensitive poloxamer gels. Moreover, polymorphic 
behavior was evaluated using XRPD and DSC measurements showing that the added surfactant 
influenced crystallization behavior. Additionally, the triglyceride-emulsifier composition also 
influenced the water uptake upon incubation, which could be confirmed by the performance of 
contact angle measurements.  
In Chapter Six the distribution behavior of lipid microparticles in suspension after injection 
into the neck and caudal thigh muscles ex vivo was evaluated. Therefore, dye-loaded particles 
were injected and distribution of the reconstitution medium, as well as the particles monitored 
by the means of surgery and ultrasound. Particles stayed at the injection site and a hydrophilic 
drug could diffuse out and distribute along the muscle fibers.  
The estrus synchronization was evaluated in Chapter Seven. The first pre-clinical study 
investigated the delivery of 750 and 3750 µg/animal in two different formulations containing 
triglycerides and 10 % GMS. The lower dose was proved to be sufficient to achieve estrus 
synchronization. Using 3750 µg/animal, neither higher synchronicity nor longer duration of 
action could be found, but the percentage of gilts that ovulated decreased significantly. The 
second study focused on the application of 750 µg/animal in formulations containing 
triglycerides, GMS and Span 40. The drug-containing system did not have statistically more 
adverse reactions and was generally well tolerated. The longest duration of cycle blockage, 
15.8 ± 4.2 days, was observed after the application of microparticles composed of 
D118 + 10 % GMS 3750 µg/animal G [6-D-Phe]. The highest synchronicity could be found 
after injection of D114 + 5 % Span 40 microparticles, where 5 out of 5 animals showed a cycle 
blockage of 6.4 ± 0.2 d. A statistically relevant delay in onset of follicular growth (after 
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13.4 ± 0.2 d) could also be observed when using D114 + 5 % Span 40 microparticles, again 
with the highest synchronicity observed. 
The long-term stability of the peptide and drug delivery system was evaluated in Chapter Eight 
over a period of twelve months. Particles were tested in terms of particle size, reconstitution 
properties, particle morphology, polymorphic forms, drug content and release behavior. Storage 
at 2-8 °C should be preferred to a storage at 25 °C, although the drug stability was not affected. 
Regarding particle size, polymorphic transition and release behavior, a storage of 2-8 °C could 
be guaranteed over the monitored time. Degradation of the peptide did not occur over 12-month 
storage. 
Several milestones in the development of a sustained delivery system for G [6-D-Phe] have 
been achieved during the work on the current thesis, foremost the incorporation of the peptide 
into spray congealed microparticles and the variation of release duration in vitro. Additionally, 
this approach was identified as a possible way for estrus synchronization. The efficacy of the 
product was confirmed in the pre-clinical studies, revealing a high tolerance and an adequate 
degree of synchronicity during the follow-up study. Storage stability was confirmed over at 
least one year.  
Future work should focus on the optimization of formulation aspects to keep the synchronous 
onset of estrus as achieved in the formulation containing G [6-D-Phe] 750 µg/animal 
D114 + 5 % Span 40, but to prolong the duration of action to 14 days in vivo as achieved in 
formulations containing 750 µg/animal G [6-D-Phe] in D118 + 10 % GMS. It should be 
evaluated whether a higher drug load could fasten the release, provide an extended duration of 
the estrus control and facilitate application as less microparticles need to be injected to achieve 
the same effective dose. The in vivo effects should be confirmed in further clinical studies or 
larger herds to evaluate the role of non-responders, adverse events and occurrence of ovulation. 
Moreover, the application of sustained release G [6-D-Phe] may be connected to the occurrence 
of permanent ovarian cysts, although we did not find statistical evidence. Since the developed 
drug delivery system was only tested in gilts, it would be of high interest if the effect is also 
present in sows. Additionally, a sterilization protocol should be developed and the influence of 
an irradiation sterilization should be evaluated.  
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